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SUMMARY
INTRODUCTION
Sentinel node biopsy (SNB) is a new technique in the management 
of cancers. The technique, which has been studied most in 
melanoma and breast cancer, involves the identification of the first 
lymph node draining a tumour and the examination of that node for 
the presence of nodal métastasés. If the sentinel lymph node (SLN) 
does not contain tumour, the implication is that the whole regional 
lymph node basin is free from tumour and a formal lymph node 
dissection can be avoided.
Prior to the start of this study, few studies had been performed on 
patients with head and neck cancer and those that were published 
were either in very low numbers or had failed in their aims. This study 
was performed to determine whether the SLN could be identified in 
patients with head and neck cancer and to determine if the SLN was 
an accurate reflector of the pathological status of the neck. If these 
aims were met, the technique could be applied as a staging 
procedure, and avoid an elective neck dissection.
METHODS
Patients with biopsy proven, single focus, mucosal malignancies of 
the upper aerodigestive tract were included in the study.
Initially, patients undergoing a neck dissection as part of their routine 
treatment were included in the study. SLN’s were firstly identified by 
injection of Patent Blue V dye only. Subsequently patients were 
injected with radiocolloid and blue dye. The radiocolloid initially used 
was Albures (a large diameter colloid) for all primary tumour sites. 
Subsequently, Albures was reserved for tumours of the tongue and
floor of mouth while Nanocoll (a small diameter colloid) was used for 
tumours at other sites. The presence of SLN’s in the neck was 
recorded, as was the levels within the neck, the presence of blue dye 
and amount of radioactivity within the SLN’s. The pathological stage 
of the remaining neck dissection specimen was also noted.
The SNB procedure was subsequently applied to a group of patients 
who would otherwise undergo observation of the neck or an elective 
neck dissection, to determine whether the procedure could be 
applied in a clinical context.
RESULTS
A total of 103 necks were explored in 96 patients with head and neck 
cancers. Each neck side was considered a single case.
SNB using blue dye alone was performed in 16 cases (in 16 
patients). SNB in the blue dye group was unsuccessful. SLN’s were 
found in only seven cases of 16 and no SLN’s contained tumour by 
routine pathology. In these seven cases, tumour was present in the 
remaining neck specimen in three cases, and in each case the SLN’s 
did not contain tumour.
SNB using a combination of blue dye and radiocolloid was performed 
in 40 clinically NO/x necks (from 37 patients). Twenty necks were 
staged pathologically NO (pNO) and 20 were pathologically involved 
with métastasés (pN+). In the pN+ cases, SLN’s were found in 36 
cases and the SLN’s was found to contain tumour, using routine 
pathology, in 16 cases of 17 where a sentinel node was found.
SNB was performed in 27 clinically N+ necks (from 25 patients) in 
patients where neck dissections were also performed, using blue dye 
and radiocolloid. In 18 cases Albures was the radiocolloid used and 
in 9 cases Nanocoll was used. In the group injected with Albures,
6SLN’s were identified in 15, tumour was found in the neck dissection 
in 12 cases, and the SLN’s contained tumour in two of these 12. In 
the group injected with Nanocoll, SLN’s were found in eight of nine, 
the neck contained tumour in eight and the SLN’s also contain 
tumour in seven of eight.
SNB using radiocolloid and blue dye was performed in 16 patients 
(17 neck sides) who did not initially undergo a neck dissection. SLN’s 
were found in all but one patient and contained tumour by routine 
pathology in two cases. These two patients subsequently underwent 
therapeutic neck dissection and post operative radiotherapy.
The amount of radioactivity within SLN’s and the size of SLN’s was 
studied. This was performed to determine whether all blue and 
radioactive nodes should be harvested in a sentinel node procedure. 
In cases where more than one blue or radioactive node was 
identified, the two largest SLN’s and the three most radioactivity 
SLN’s were sufficient to stage the neck for tumour métastasés
Three necks were explored for sentinel nodes in two patients with 
oral melanoma. SLN’s were found in both patients, and melanin 
containing macrophages were found in the SLN of one patient.
CONCLUSIONS
In head and neck cancer, SNB to stage the neck is best performed in 
the clinically NO neck using a combination of radiocolloid and blue 
dye injection. The use of the SNB procedure in the clinically involved 
neck is not accurate but the sensitivity of the procedure increases 
when a small diameter colloid is used. The presence of radioactivity 
in the neck is a reflection of lymphatic transport from the injection site 
to the SLN’s and the choice of radiocolloid should be dependent on 
the anatomical site of the primary malignancy. It is possible to locate
SLN’s in the neck, when no other elective neck surgery is performed, 
using a smaller incision than that for a neck dissection. The true 
sensitivity of SNB in this context is unknown but will become 
apparent with time. In patients with head and neck cancer, with 
tumours accessible to injection without the need for general 
anaesthesia, the SLN accurately stages the neck and should be 
investigated in larger multi centre trials. Such a trial has been initiated 
as a result of the work within this thesis.
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CHAPTER 1: INTRODUCTION
GENERAL INTRODUCTION TO ORAL AND OROPHARYNGEAL 
CANCER
Oral cancer and oropharyngeal cancers are malignant 
transformations of the mucosa of the oral cavity and oropharynx. The 
commonest malignant transformation of the mucosa in these areas is 
a squamous cell carcinoma (SCC). SCC’s of these anatomical sites 
behave similarly to SCC's of other sites within the mucosa of the 
upper aerodigestive tract and are commonly termed “Head and neck 
cancers" (Table 1 ).
Within this Thesis, the terms “head and neck cancer”, “oral cancer” 
and “oropharyngeal cancer” refer only to cancers that can be 
visualised through the oral cavity and will include oral cavity and 
some oropharyngeal malignancies. These terms will be used 
interchangeably.
Head and neck cancer represents approximately 2-5% of all 
t umours^ In  Scotland the incidence of oral cancer is rising. In 1975, 
there were 8 8  cases of oral cancer in Scotland; by 1996 there were 
204 cases (Figure 1 ). In Scotland, oral cancer trends are collected by 
the Scottish Cancer Intelligence Unit which produces cancer 
registration statistics for Scotland and publishes the data on the 
internet (http://www.show.scot.nhs.uk/isd/cancer/facts_figures/types
/oral.htm).
Worldwide, the incidence of oral cancer is also increasing. In 1994, 
Macfarlane and co-workers examined World Health Organization 
data. Cancer registry data was available from 24 countries and a 
rising incidence in men was noted in 19  ^ but not in women'^. The
18
incidence in women is likely to rise, since the use of tobacco, an 
important aetiological factor, in women is rising.
Aetiological factors are well documented for oral cancer. Tobacco 
use has a synergistic effect with alcohol use and in the Western 
world, these are the most important causative factors. In many 
countries, use of the areca or betel nut is associated with oral cancer 
and less common factors include human papilloma virus infection, 
syphilis and sideropaenic dysphagia^. Poor socio-economic status, 
poor oral health and poor diet are common associations.. Pre- 
malignant lesions are well recognised in oral cancers and these 
include leukoplakia and erythroleukoplakia®’®.
The management of oral cancer is continually evolving '^®. Surgery to 
the primary lesion either alone or in combination with radiotherapy is 
the most effective form of treatment for head and neck cancer. 
However, despite a greater understanding of the natural history of 
the disease®, survival for oral cancer has not improved over the past 
few decades^®' "^ .^ The suggestion is that there is a deficiency of 
public and professional awareness and education regarding the early 
diagnosis of oral cancer and oral health information in general. 
Continued smoking and drinking increases the risk of developing 
metachronous second primatY cancers of the upper aerodigestive 
tract, an important cause of death in survivors of more minor head 
and neck cancers^®.
Late presentation of oral cancer is associated with poor survival rates 
for many reasons. Mainly, however, local and regional recurrence 
follows initial treatment^® or the disease is untreatable at the time of 
presentation^^. Approximately 50% of patients that die from oral 
cancer die with local recurrence and 70% with neck metastasis. 
Regional metastasis with carotid erosion is the direct cause of death 
in approximately 1 0 % of patients^®.
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If loco-regional failure can be improved, overall survival rates can 
also be improved. It is thought that one means of improving 
subsequent regional disease is the early treatment of neck 
me ta s ta s i s ^ an d  this has brought about the concept of elective 
treatment of the neck.
THE CERVICAL LYMPH NODES IN HEAD AND NECK CANCER
Head and neck cancer spreads via lymphatics to the regional 
draining lymph nodes in the neck. This spread is thought to be 
embolic in nature^^. The presence of lymph node metastasis is one of 
the most important prognostic factors in head and neck cancer, 
decreasing five year survival by 50%, from approximately 90% in 
those patients with no lymph node disease to 40% for those with 
nodal metastasis^®. Reliable staging of the neck is important in 
determining appropriate management. If nodal metastasis is present, 
aggressive treatment protocols are followed^®, with the patient 
undergoing surgical ablation of the nodal basin and post operative 
external beam radiotherapy. However, if nodal metastasis is absent, 
by definition the patient does not require treatment of the regional 
nodal basin and can avoid surgery and radiotherapy. Accurate 
knowledge of the presence of nodal disease thus alters prognosis, 
staging information and disease management.
There is no accurate non surgical method for determining the 
presence or absence of nodal metastasis^^. The only consistently 
reliable means of detecting lymph node disease is by pathological 
examination of the lymph nodes. Physical examination of the neck is 
an unreliable means of assessing nodal involvement^® as are 
radiological imaging techniques^®. These include computed 
tomography (CT), ultrasound scanning (USS), and magnetic
20
resonance imaging (MRI), all of which have recognised margins of 
error and their use as staging modalities remains controversial®®'®^
Neck staging using USS, MRI and CT assumes that large nodes are 
cancerous and small nodes are free of cancer®®. Whilst this is 
generally true, other criteria used to assess the presence of tumour 
within lymph nodes include the presence of extracapsular spread and 
a heterogeneous attenuation within the node®®. The presence of 
these factors, even within small lymph nodes, would upstage the 
neck by radiological imaging®* .^ The size range of normal lymph 
nodes varies with the anatomical position of the node within the neck. 
The critical size for predicting tumour involvement is greater than 
1cm except for level II nodes, the upper jugular region, where a 
critical size of 1.5cm is used®®’®®.
By combining USS with fine needle aspiration cytology (USGFNAC) 
of the neck, the sensitivity of USS of the neck rises to 82%® ,^ 
however, to achieve these figures it is necessary for an experienced 
radiologist to perform the procedure®® and structures immediately 
adjacent to bone and air lose definition on scanning.
In a recent meta-analysis of lymph node métastasés detected by CT 
and clinical examination®®, Merritt and co-workers found that the 
sensitivity of CT scanning of the neck to identify a neck with nodal 
disease was 83%, whereas that for physical examination was 74%; 
the specificity of CT was 83%, whereas that for physical examination 
was 81%. MRI scanning adds little additional diagnostic information 
compared to CT scanning of the neck, but has the additional
disadvantages of greater motion sensitivity, patient intolerance from 
claustrophobia, greater expense and time requirement and 
interference from metallic bodies.
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Positron emission tomography (PET) with 18-fluorodeoxyglucose 
(18-FDG) has been used as a research tool since the early IQQO’s"^ ®. 
18-FDG-PET scanning is a functional imaging technique, which relies 
on the greater metabolism of glucose by malignant cells than by 
normal cells. The increased metabolism by tumour cells is seen as 
an increased area of radioactivity during a PET scan. Potentially, 
PET scanning overcomes the inherent anatomical limits of imaging 
modalities such as CT, MRI and USS since small métastasés may 
still be detected and large lymph nodes that do not contain tumour 
will not be highlighted as malignant. Reports on its success have 
been variable in detecting lymph node métastasés. The sensitivity of 
PET varies from 50% - 100% and the specificity varies from 89% - 
9 9 0 /^4 3 -5 0 P2 T scanning has the advantage of being able to scan the 
whole body for distant as well as regional métastasés. Flowever, the 
sensitivity of PET scanning in melanoma when compared with 
sentinel node biopsy is only 17%®^  because of the minute tumour 
volumes in the sentinel nodes of melanoma patients. Additionally, 
because of the prohibitive expense of the cyclotron required to 
generate the radiopharmaceuticals used during PET scans, the 
technique is only available in a few centres. In 2000, Scotland had a 
single PET scanner in Aberdeen, set up as research equipment and 
not for routine clinical use,
MANAGEMENT OF THE NECK
Approximately one-third of patients with cervical lymph nodes 
apparently free of tumour contain métastasés in neck dissection 
specimens®®. This varies with anatomical site, T-classification and 
tumour depth of invasion.
The treatment of early neck disease carries a better prognosis than 
the treatment of late neck disease®®,.
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Because of the high rate of occult nodal metastasis, and because the 
treatment of early nodal disease is prognosticaliy better than the 
treatment of late nodal disease, a clinical decision to treat the neck 
electively is often made.
A “wait-and-see” approach to all patients with clinically clear necks 
would result in a high proportion of patients subsequently developing 
late stage, possibly unsalvageable, nodal disease, arising from their 
occult métastasés®®. Conversely, performing neck dissections on all 
patients with clinically clear (NO) necks would lead to a high 
proportion of unnecessary lymph node dissections.
Finally, approximately 10-33% of clinically node positive patients are 
found to be free of tumour in the neck following a neck dissection and 
pathological examination of their lymph nodes®^ ,®®.
Thus, the management of the neck in patients with head and neck 
cancer is controversial
Current protocols for the management of the neck are locally 
determined®®. At Canniesburn Hospital, if the patient is medically fit 
enough to undergo a neck dissection, it will be performed for 
palpable lymphadenopathy or if it is thought that the chances of 
occult metastasis is greater than 20%; this includes patients with T1 
tongue tumours with a maximum tumour thickness greater than 4 
mm determined by initial incisional biopsy and for stage 2, 3 and 4 
disease. Thus all patients with nodal métastasés on palpation will 
undergo a therapeutic neck dissection, and patients who are thought 
likely to harbour covert métastasés will undergo an elective neck 
dissection.
23
NECK DISSECTION
History credits Warren as first describing the excision of a neck 
carcinoma in 1847®°, Kocher first describing the excision of the 
submandibular lymph nodes in a case of tongue carcinoma®^ and in 
1888, the Polish surgeon Jawdynski described a procedure which 
detailed the removal of the cervical lymph nodes® .^ However, it was 
not until the neck dissection was first described in English by Crile in 
1906®® and later popularised by Martin in 1944®  ^ that the technique 
for surgical excision of the lymph nodes in the neck for a cancer 
gained acceptance.
Morbidity following a classical radical neck dissection (RND) can be 
fairly considerable®®’®®, with complications including shoulder and 
neck pain and immobility, lymphocoele formation, wound 
complications and aesthetic imbalance®^. In addition, bilateral 
classical RND’s will lead to severe plethora, facial oedema and poor 
neck movement®®'^®. Surgeons are reluctant to perform elective neck 
dissections for patients with suspected early disease to avoid 
unnecessary surgery, yet the treatment of early neck disease carries 
a better prognosis than the treatment of late neck disease®®. 
Accordingly, the decision to perform a radical lymph node dissection 
on a patient with no evidence of métastasés can be difficult^^’^ .^
Surgical philosophy has evolved over the past few decades. Less 
radical surgery has developed to reduce morbidity and the surgical 
insult but be equally effective^®. Neck dissections have evolved in a 
similar way following its popularisation by Martin "^ .^ Bocca described 
the functional neck dissection in 1980, realising that less radical 
surgery was not necessarily less effective^®.
The neck dissection procedure has been modified extensively since 
its original description by Crile to reduce morbidity and a host of
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confusing terms applied to the variations. A review of neck dissection 
terminology was performed by Robbins^®’^  in which he outlined the 
consensus report on neck dissection terminology by the American 
Academy of Otolaryngology -  Head and Neck Surgery. These more 
accurate and descriptive terms are used throughout this Thesis and 
the terminology is summarised in tables 3 and 4. A radical neck 
dissection is the standard neck dissection from which all others are 
compared and is similar to that described by Crile and Martin. A 
modified radical neck dissection (MRND) is a neck dissection which 
excises the same lymph nodes as a radical neck dissection, but 
preserves one or more of the internal jugular vein, the 
sternocleidomastoid muscle and the spinal accessory nerve, usually 
removed in a radical neck dissection. A MRND is often used in 
patients with mobile lymphadenopathy. A selective neck dissection 
(SND) is one in which some of the nodes are deliberately left behind 
in the neck, a procedure often used in elective neck dissections. 
Finally, an extended neck dissection is one in which the nodal 
dissection goes beyond the nodal groups described by Crile and is 
often used when palpable lymphadenopathy is present outside the 
nodal areas of a radical neck dissection.
Radical neck dissection reduces quality of life for patients more than 
a MRND, which in turn is a greater burden than a SND^®. Shoulder 
dysfunction, in particular, is significantly worse following a RND 
compared with a MRND and SND and the more radical procedures 
are associated with greater pain post operatively.
The neck is divided into levels for convenience and to permit a 
common language for head and neck surgeons (Figure 2). Level I 
nodes are found in the submental and submandibular triangles, 
levels II, ill and IV are the upper, middle and lower internal jugular 
chain of lymph nodes and level V is the posterior triangle. Level II is
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further divided into level Ha and Mb. Level lib is the area of the upper 
jugular lymph nodes bound interiorly by the spinal accessory nerve 
and level lia is defined as the nodes inferior to the spinal accessory 
nerve. Level Mb nodes are more difficult to excise in a neck 
dissection and there is controversy surrounding the need for its 
exploration during a neck dissection^®.
The consensus report on neck dissection terminology states that a 
RND is as described by Crile, excising the lymph nodes in levels l-V 
and including the spinal accessory nerve (SAN), sternocleidomastoid 
muscle (SCM) and internal jugular vein (IJV). A comprehensive neck 
dissection is one which removes all draining nodal tissue. Those 
procedures in which levels l-V are excised but one or more of the 
three non-lymphatic structures are spared are called modified radical 
neck dissections (MRND). A neck dissection which excises nodal 
tissue beyond levels l-V is termed an extended RND. A neck 
dissection which leaves one or more of the nodal tissue from levels I- 
V within the neck is called a selective neck dissection, and usually 
spares the IJV, SAN and SCM. Selective neck dissections may be 
described according to the levels that are removed or may be termed 
descriptively.
Controversies exist amongst clinicians as to which type of neck 
dissection is most appropriate for varying disease patterns. The 
management of the clinically NO neck®  ^ is more controversial than 
that of the clinically N+ neck®®. The more radical the dissection, the 
greater the likelihood of significant morbidity arising from the 
procedure®^ Conversely, the less nodal tissue removed, the more 
likely it is to leave nodal tissue possibly infiltrated with malignancy®^. 
Also, sparing of non-nodal structures is technically more demanding 
than a traditional RND, and therefore increases the time spent by the 
patient under general anaesthesia. Cadaveric studies which have
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detailed anatomical drainage pathways of the mucosa of the head 
and neck®® as well as retrospective clinical data®'^  suggest that an 
elective lymph node dissection clearing levels l-lll will remove the 
lymph nodes most at risk of harnouring occult metastasis for oral 
cancers^®. Additionally, retrospective studies examining the patterns 
of lymph node métastasés in head and neck cancer have confirmed 
the rarity of nodal disease within levels IV and V in cases where 
nodal involvement of levels l-lll is absent®®. This is confirmed 
clinically, where tumour recurrence has been found to be 
approximately 5% following a SOHND for clinically NO disease®®.
At Canniesburn Hospital, suspected malignancy is treated, if 
possible, with an MRND-III (Figure 3, Table 5) and a level l-IV 
selective neck dissection is often used as a staging procedure. 
Sparing of as many non-nodal structures as possible for functional 
preservation remains one of the principles of the Canniesburn 
management philosophy, especially in the management of the 
clinically NO neck.
SENTINEL NODE BIOPSY
The sentinel node concept (Figure 4) states that when a tumour 
metastasises via lymphatics, it does so firstly to one of the lymph 
nodes directly draining the tumour®^. These lymph nodes are termed 
the sentinel nodes and these nodes are the first echelon lymph 
nodes in the regional lymph node basin draining that particular 
tumour®®. There may be one or several sentinel nodes for a patient 
and a particular tumour. For clarity and to avoid clumsy terminology, 
hereafter sentinel nodes will be referred to in the singular, 
acknowledging that several sentinel nodes may be found in one 
patient.
:î
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The concept also states that if the sentinel node can be identified and 
retrieved, and if detailed pathological examination of the sentinel 
node is performed, it will be a true reflector of the positivity or 
negativity of the presence of lymph node métastasés in the regional 
drainage basin®®. A sentinel node free of tumour indicates the lack of 
regional tumour métastasés.
By implication, it can be seen that a patient with a carcinoma need 
only undergo sampling of the sentinel node to determine the 
presence or absence of lymph node métastasés, rather than a formal 
regional lymph node dissection. The concept is illustrated in Figure 4.
HISTORY OF SENTINEL NODE BIOPSY
The sentinel node concept was first postulated by Gould in 1960 in a 
presentation to the James Ewing Society, the forerunner of the 
Society of Surgical Oncology. He suggested that parotid cancers 
spread initially to what he termed an “angular node” located at the 
junction of the anterior and posterior facial veins, and that this lymph 
node could be sampled for frozen section histological analysis 
(Figure 5). The absence of metastasis in this node would negate the 
need for further treatment or investigation of the regional lymph 
nodes.
The sentinel node concept was revisited by Cabanas in 1977®®, 
unaware of Gould’s previous experience. His work on penile SCO 
permitted the identification of the site of the first draining lymph 
nodes in the groin from a primary carcinoma on the skin of the penis. 
Cabanas found the position of the sentinel node by performing 
lymphoscintigraphy of the dorsal penile lymphatics. The nodal group 
was identified near the superficial epigastric vein in the groin and the 
recommendation of Cabanas was selective lymphadenectomy of this 
group of nodes to determine the presence or absence of lymph node
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métastasés. Cabanas’ work fell into disrepute after further studies 
highlighted the unreliability of the sentinel node as a predictor of the 
remaining basin, with reports of false negative results, and criticism 
of his follow-up methodology® '^®" .^
It was not until 1992 when Morton described a technique for 
identifying the sentinel node in cutaneous malignant melanoma 
(MM)®®, following experimental work in a feline model®®, that the 
concept of sentinel node biopsy became more firmly established. 
Morton’s fundamental conceptual difference was that the location of 
the sentinel node was dependant on the individual’s lymphatic 
drainage pattern and the site of the primary malignancy. Unlike 
Gould and Cabanas, Morton suggested that the position of the 
sentinel node varied with each individual and that a tracer injection 
would be required for each patient undergoing the procedure.
The sentinel node was successfully identified, after a learning curve, 
by injection of a vital blue dye (lymphazurin blue or Patent Blue V, 
Figure 6) into the dermis around the excised tumour, following blue 
stained lymphatics to the first lymph node and harvesting that node 
for routine and immunohistochemical histological evaluation. For 
areas of equivocal lymph drainage, a radiocolloid was injected pre- 
operatively to identify the regional basin by lymphoscintigraphy. 
Subsequent work at the Moffit Cancer Institute in Florida showed that 
the sentinel node was a highly accurate reflector of the remaining 
lymph node basin and that melanoma métastasés progressed 
through the regional lymph nodes in an orderly manner® .^
The method described by Morton for sentinel node biopsy in 
malignant melanoma was subsequently adapted to improve the 
detection of potentially elusive nodes. Originally, per-operative blue 
dye injection was used to identify sentinel nodes and in cases where 
there was equivocal lymphatic drainage of the primary tumour,
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Morton’s team used pre-operative lymphoscintigraphy to identify the 
drainage basin. However, even when using pre-operative 
lymphoscintigraphy, difficulties with this procedure arose when blue 
stained lymphatics were not visualised. Intra-operative use of a hand 
held gamma counter (Figure 7) was shown to be an alternative 
means to identify the sentinel node in humans®®, following work on a 
feline model®®. The accepted current method for sentinel node biopsy 
involves the administration of both blue dye and radiocolloid, 
especially in head and neck melanoma®®. When using 99m-Tc 
labelled colloids in the sentinel node procedure, radiation doses to 
surgeons and pathologists are documented as being minimal^ ®®'^ ®^ . 
Since its successful application in cutaneous melanoma, the 
technique has been applied to a host of different tumours. In 
particular in breast carcinoma, where the technique was first 
described in 1993 by Krag^ ®®, the sentinel node concept has been 
extensively studied. Other tumours which have been investigated 
with sentinel node biopsies include: Merkel cell tumours^®" '^^^\ 
colorectal c a r c i n o m a ^ v u l v a l  cancer^ ^®"^ ^®, penile carcinoma^®®, 
cutaneous lymphoma^®^and cutaneous squamous cell carcinoma^®^.
LYMPHOSCINTIGRAPHY IN SENTINEL NODE BIOPSY
Lymphoscintigraphy and gamma probe guided localisation have 
emerged as useful additional techniques for identification of the 
sentinel node, since Morton’s original description with blue dye 
alone^ ®®'^ ®®. A radioisotope labelled colloid is injected into or around a 
tumour or its excision site; in the case of lymphoscintigraphy, a 
scintillation counter is used to identify areas of radioactivity within the 
regional lymph node basin and in the case of gamma probe 
localisation, a small hand held Geiger counter isolates radioactive
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lymph nodes during surgery. The use of a radiocolloid does not 
prevent the use of blue dye.
Dynamic lymphoscintigraphy produces real time images of 
radiocolloid as it passes through lymphatic vessels to sentinel lymph 
nodes and static lymphoscintigraphy permits the identification and 
localisation of lymph nodes where the colloid collects^ ®®"^ ®®. The 
investigation, when used in conjunction with a 99m-Technetium 
(99mTc) labelled colloid, is performed up to 24 hours prior to surgery, 
although the exact timing is a matter of debate^®®. In gamma probe 
guided surgery, a hand held radioactivity detector, such as the 
Neoprobe® (Neoprobe Corp, Dublin, Ohio, USA) is used to locate 
radioactive lymph nodes within the operating field for excision.
Different radioactive colloids have varying pharmacokinetic and 
pharmacodynamic properties but no available radiocolloid achieves 
the properties of the ideal colloid "^^ ®. Small diameter colloids easily 
enter the terminal lymphatics and travel quickly to the sentinel node. 
However they are likely to pass from the sentinel node to second, 
third and subsequent echelon lymph nodes^"^\ Examples of small 
diameter colloids include Nanocoll (with a mean particle size 
diameter of 80nm), Filtered Sulphur Colloid (mean particle size 
diameter of 200nm) and Antimony Sulphur Colloid (5nm mean 
particle size diameter). Nanocoll is available in the European 
Community, Filtered Sulphur Colloid is available in the United States 
of America and Antimony Sulphur Colloid is available in Australia. 
Conversely, a large diameter colloid is slow moving, and so remains 
within the first echelon lymph node. However, the colloid is less likely 
to pass into lymphatic vessels. Examples of large diameter colloids 
include Albures, and Unfiltered Sulphur Colloid, with mean particle 
size diameters of 500nm. Currently, Albures is only available in the
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European Community and Sulphur Colloid is only available in the 
USA.
Until the ideal colloid is developed the arguments for using different 
colloids will persist. Two radiocolloids of human serum albumin were 
available for use in this study: Albures and Nanocoll.
THE SENTINEL NODE IN HEAD AND NECK CARCINOMA
Prior to the start of this study, initial results of the sentinel node 
procedure in head and neck cancer had been reported with mixed 
success. Pitman et al were unable to find any blue nodes in patients 
injected with blue dye alone "^^ ,^ and in a series of five cases using 
radiocolloid alone, Koch et al remained unconvinced of its role in the 
management of head and neck cancer patients "^^®. The first case 
report of a successful sentinel node biopsy in head and neck cancer 
using radiocolloid to trace the first echelon node was performed in 
1996 by Alex and Krag on a patient with a supraglottic carcinoma "^ "^  ^
and in 1998, Bilchik et al reported the use of sentinel node biopsy in 
a variety of neoplasms, including five patients with head and neck
1 4 5cancer .
Since lymph node metastasis in Head and Neck carcinoma is 
thought to be embolic in nature, the concept of identifying the first 
node to which the tumour spreads, harvesting and subsequently 
examining that node in detail for the presence or absence of 
metastasis and using this as an indicator for the remaining cervical 
nodes is an appealing prospect. The technical aspects of the 
procedure require validation.
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LYMPH NODE HISTOPATHOLOGY IN HEAD AND NECK 
CARCINOMA
Lymph node metastasis is initially seen at the subcapsular sinus of 
pathologically involved lymph nodes (Figure 8)^ "^ ®. Flow of lymph and 
cancer cells within the lymph node is then directed to the more 
central regions of the node "^^ .^ As the node becomes infiltrated with 
carcinoma, a response to the tumour cells is thought to occur and the 
lymph node undergoes reactive enlargement^"^®’ "^^®. Multiple serial 
sections of a node will identify a greater proportion of nodes with 
metastatic disease^®®, and the greater the search for cancer cells, the 
greater the chance of finding them. Following a lymph node neck 
dissection, approximately 20-30 nodes on average are removed from 
the regional basin® .^ Each node requires examination. The method 
for routine pathological examination of lymph nodes can vary 
between institutes. In the Oral Pathology Unit at the Glasgow Dental 
Flospita! and School, lymph nodes from a neck dissection specimen 
are bisected through their hilum or largest diameter if the hilum is not 
obvious. One half of the node is processed and cut for routine 
staining with Haematoxylin and Eosin (H&E). Microscopic 
examination of the bisected node is used to detect squamous cells, 
which initially manifest themselves at the peripheral sinus. Greater 
sampling of the node and the use of immunohistochemistry will lead 
to greater detection of lymph node métastasés and will upstage the 
neck of the patient from NO to N+ in approximately 10%^® ’^ ®^^. 
However, it is not known whether this is prognostically significant, 
when performed in the context of a neck dissection^"^®’ ®^®. In other 
carcinomas, however, applying special staining techniques to 
multiple blocks of the sentinel node is a requirement to accurately 
examine the sentinel node^ ®"^ .
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AIMS
The sentinel node concept is an attractive one to apply to head and 
neck cancer. The main aim of this study was to develop a 
standardised, effective and reproducible technique for sentinel node 
biopsy in head and neck cancer. Specifically, the aims were:
» To formulate a method for the identification of the sentinel 
lymph node in patients with squamous cell carcinoma or 
malignant melanoma affecting accessible areas of the upper 
aerodigestive tract.
• To determine whether sentinel node biopsy can be used as a 
means to accurately determine the presence or absence of 
lymph node métastasés in patients with oral cancer.
• To map the anatomical site of the sentinel node in head and 
neck carcinoma in a graphical format for various sites of 
primary lesion.
• To perform sentinel node biopsy on patients undergoing no 
elective treatment to the neck, after refinement of the initial 
methodology.
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TABLES AND FIGURES
Figure 1: Incidence of Oral Cancer in Scotland 1975-1996 
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Figure 2: Neck Dissection Levels
(original in colour)
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Figure 3: An MRND-lll. The specimen has been marked to 
indicate the dissection levels.
(original in colour)
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Figure 4 : The sentinel node concept
(original in colour)
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Figure 5: Patient with parotid malignancy and nodal métastasés 
in the angular node
(original in colour)
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Figure 6: Patent Blue V Dye
(original in colour)
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Figure 7: The Neoprobe 1500 and probes
(original in colour)
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Figure 8: Metastatic disease in the subcapsular sinus of a lymph 
node
(original in colour)
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Table 1: ICD-9 codes for head and neck cancer
140 Malignant neoplasm of lip
141 Malignant neopiasm of tongue
142 Malignant neoplasm of major salivary glands
143 Malignant neoplasm of gum
144 Malignant neoplasm of floor of mouth
145 Malignant neoplasm of other and unspecified parts of mouth
146 Malignant neopiasm of oropharynx
147 Malignant neopiasm of nasopharynx
148 Malignant neopiasm of hypopharynx
149 Malignant neoplasm of other and ill-defined sites within the lip, 
oral cavity, and pharynx
150 Malignant neopiasm of oesophagus
160 Malignant neoplasm of nasal cavities, middle ear, and 
accessory sinuses
161 Malignant neoplasm of larynx
193 Malignant neopiasm of thyroid gland
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Table 2; TNM clinical staging of SCC of the oral cavity and 
oropharynx^®®.
I X Tumour size cannot be assessed, e.g. unknown primary
is Carcinoma in-situ
1 Tumour size ^cm
2 Tumour size 2-4cm
3 Tumour size >4cm
4 Tumour invading deeper structures
N X Regional lymph node status cannot be assessed
0 No nodal métastasés
1 Metastasis in single ipsilateral node, âcm in greatest 
dimension
2a Metastasis in single ipsilateral node >3cm but ^cm in greatest 
dimension
2b Métastasés in muitiple ipsilaterai nodes, none >6cm
2c Métastasés in bilateral or contralateral nodes, none >6cm
3 Metastasis in a node >6cm in maximum dimension
M X Distant métastasés cannot be assessed
0 No distant métastasés
1 Distant métastasés present
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Table 3: Stage Grouping
Stage i T1N0M0
Stage 11 T2N0M0
Stage III T3N0M0, T1/2/3N1M0
Stage IV T4N0M0, T4N1M0, anyTN2/3M0, any l anyN M1
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Table 4: Neck dissection levels
Level of Neck 
Dissection
Anatomical Description
i Submandibular triangle and submental triangle.
Anatomical borders: lower border of the 
mandible and the bellies of the digastric 
muscle; hyoid bone and the midline.
II Upper jugular nodes.
Anatomical borders: skull base to bifurcation of 
common carotid artery at the level of the hyoid 
bone; lateral border of sternohyoid muscie to 
posterior border of sternocleidomastoid.
III Middle jugular:
Anatomical borders: inferior border of level II to 
the omohyoid muscle at the level of the 
cricothyroid membrane; lateral border of 
sternohyoid muscle to posterior border of 
sternocleidomastoid.
IV Lower jugular:
Anatomical borders: from the inferior border of 
level III to the clavicle; lateral border of 
sternohyoid muscle to posterior border of 
sternocleidomastoid.
V Posterior triangle
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Table 5: Neck Dissection Terminology
Terminology Description
RND Radical neck dissection excising 
levels l-V, including the SAN, IJV 
and SCM
MRND-I Excising levels l-V, including the 
IJV and SCM
MRND-II Excising ievels l-V, including the 
IJV
MRND-III Excising levels l-V, all three non­
lymphatic structures spared
Extended Neck Dissection Excision of levels l-V with further 
dissection continued to deeper 
structures (e.g. pharyngo-laryngeal 
nodes, tracheo-oesophageal 
nodes, parotid nodes, etc)
Selective Neck Dissection Excision of up to four levels of 
cervical nodes, usually sparing 
some or all non-lymphatic 
structures
SOHND Supraomohyoid neck dissection, 
excising levels l-lll, sparing all non­
lymphatic structures
Anterolaterai Neck Dissection Excision of levels ll-IV
Posterolateral Neck Dissection Excision of levels ll-V
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Table 6: Properties of the ideal colloid140
Licensed product
Narrow particle size range
99mTc label
Stable on storage
Lymph channel transport
Rapid transport
Retention in sentinel node
Stable in blood (no shrinkage or 
growth)
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CHAPTER 2: INITIAL METHOD WITH BLUE DYE ALONE 
INTRODUCTION
The original method for sentinel node biopsy in the field of cutaneous 
malignant melanoma described a technique using blue dye alone® .^ 
The dermis surrounding the melanoma or the site of excision biopsy 
was injected with blue dye. An incision was made into the regional 
lymph node basin and blue stained lymphatics were followed to blue 
stained lymph nodes. In areas of the skin with uncertain lymphatic 
drainage, preoperative lymphoscintigraphy identified the nodal basin 
to be explored. Using the blue dye technique, sentinel node biopsy 
was found to be a reliable method for identifying sentinel nodes in 
regional lymph node basins. The technique using blue dye alone has 
been used for both melanoma and breast cancer. In a study of 
cutaneous head and neck melanoma sentinel node biopsy, blue dye 
was used to locate a sentinel node in 90% of cases^^®.
Our initial study was performed to investigate the possibility of 
performing sentinel node biopsy with blue dye alone, in patients with 
squamous carcinoma of the head and neck. The alms of the study 
were to determine whether the sentinel node was identifiable 
following blue dye injection and to determine if the absence of tumour 
within the sentinel node implied the absence of tumour within the 
whole lymph node basin.
MATERIALS AND METHODS
Patients undergoing a neck dissection as part of the surgical 
treatment for histologically proven single focus primary SCC, were 
invited to enter the study between April 1998 and July 1998. All 
patients had biopsy confirmed SCC and had undergone examination
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of the tumour and neck under anaesthesia for assessment of clinical 
stage, resectability and the presence of multi-focal disease.
At operation a tri-radiate incision was made in the neck and 
subplatysmal skin flaps raised (Figure 9). 0.5-1.0 ml of Patent Blue V 
dye (Laboratoire Guerbet, Aulnay-Sous-Bois, France) was then 
injected throughout the normal mucosa and submucosa surrounding 
the tumour. If the sternomastoid muscle was to be preserved, this 
was separated from its investing fascia and retracted posteriorly to 
expose the deep cervical chain of lymph nodes. Blue stained 
lymphatics, if seen, were followed to a blue lymph node, which was 
harvested. The remainder of the neck dissection then continued as 
normal. Following the procedure the dissected specimen and the 
neck wound bed were examined for residual blue dye in an attempt 
to ensure the successful harvesting of all blue stained sentinel 
nodes. Dissected neck specimens were marked for orientation by the 
pathologist and placed in formalin.
The sentinel nodes were fixed in 10% neutral buffered formalin and 
after fixation were bisected through the hilum or largest diameter if 
the hilum was not identifiable. As per the departmental policy for 
examining lymph nodes from regional lymph node dissection 
specimens, if the thickness of the halves was more than 
approximately 2mm the slices were further trimmed to provide 
additional 2mm thick blocks, thereby increasing the chance of finding 
metastatic tumour. The remainder of the neck specimen was 
dissected and all nodes over approximately 2.5mm in maximum 
diameter were identified in their anatomic groups. Each node was 
bisected and one half was processed for histological examination. 
One H&E stained section was prepared from each block and was 
examined for the presence of nodal involvement by tumour.
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RESULTS
16 necks were explored for sentinel nodes. Each neck side was 
considered a single case. Eight cases were classified clinically as NO 
and eight were clinically involved with tumour (N+).
In the NO group, four cases were pathologically NO (pNO) and four 
were pathologically involved with métastasés (pN+). In the pNO 
group, a single sentinel node was found in each of the four necks, 
and the sentinel node was free of tumour (by definition). In the 
clinically NO group that was pN+, a sentinel node was found in two 
cases, but no tumour was found in the sentinel nodes when 
examined using conventional histology.
In the N+ group, seven cases were confirmed as pN+ and one case 
was pNO. In the pN+ group, a sentinel node was found in one neck, 
and did not contain tumour. In the pNO case no sentinel node was 
found.
In all cases, when the neck dissection specimen was examined ex- 
vivo for further evidence of blue nodes, none were seen. Additionally, 
no blue stained lymphatics were seen in the neck following 
completion of the surgical procedure.
In summary, sentinel nodes, identifiable by blue dye alone, were 
found in seven cases out of 16 and no sentinel node contained 
tumour, despite the presence of nearby metastasis in 11.
DISCUSSION
This study was undertaken to determine whether blue dye sentinel 
node biopsy could be used as a method of identifying sentinel nodes 
in the neck for head and neck cancer patients. The technique of 
using Patent Blue V dye alone was unsuccessful not only in the 
identification of sentinel nodes within the neck in all patients but also
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in identifying involved sentinel nodes in the presence of neck 
metastasis.
The main difficulty encountered with the blue dye technique was in 
failing to identify blue nodes and blue lymphatics. Since these were 
not identified in the majority of cases, the majority of first echelon 
nodes were not harvested. When sentinel nodes were seen and 
harvested, the blue nodes did not reflect the pathology of the neck.
The reasons for this failure could have been in the surgical technique 
or the pathological technique.
Blue nodes could have been present in the neck, but may have been 
missed during the biopsy part of the procedure. Only seven sentinel 
nodes were identified in our initial study, and sentinel nodes were not 
seen in nine cases -  clearly all first echelon nodes were not identified 
in all necks. Even in cases where a sentinel node was found, other 
first echelon nodes remained unidentified and false negative results 
were obtained.
The sentinel nodes identified may have contained small deposits of 
tumour, but not in the sections examined histologically. In melanoma 
and breast cancer sentinel node biopsy, the sentinel node is only an 
accurate reflector of the regional nodal basin when it is examined in 
detail^^ '^^^®. This may or may not be the case in head and neck 
cancer sentinel node biopsy, however, in order to determine whether 
this were true, sentinel node biopsy was subsequently performed 
using a radiocolloid tracer in addition to blue dye to determine 
whether the reason for failure was the failure to see the blue sentinel 
nodes.
Although the technique for sentinel node biopsy using blue dye alone 
has been used successfully in melanoma and breast cancer^®°’^®\ 
the technique in head and neck cancer may be more technically
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demanding. The fibrofatty tissues of the axilla and groin, where 
lymph nodes are located, are relatively easy to explore. Both regions 
have fewer structures of vital importance than the neck and it may be 
that dissection of the fibrofatty parenchyma of the groin and axilla, 
searching for blue stained lymphatics, is more straightforward than 
exploration of the neck.
Injection of blue dye is simpler for cutaneous lesions, where there is 
a well defined and semi rigid dermis with abundant lymphatic 
concentration. No such layer exists for mucosa and blue dye can be 
taken up by the venous drainage rather than the lymphatic drainage.
Pathologically involved nodes may not take up blue dye because the 
increase in hydrostatic pressure as a result of tumour métastasés 
diverts lymphatic flow to non-involved nodes.
There is a well recognised learning curve for sentinel node biopsy in 
cutaneous melanoma. If a single surgeon compares the rate of 
sentinel node identification in his first 30 cases with that of his 
subsequent 30 cases, he will see an increase. The learning curve 
flattens after this number of cases and so it has been suggested that 
approximately 30 cases should be performed by surgeons learning 
the procedure^® '^^® ,^ although the exact figure varies with individual 
surgeons, type of cancer and technique used for sentinel node 
biopsy.
Our experience with blue dye alone was our first experience with 
sentinel node biopsy in head and neck cancer. In view of the learning 
curve, another reason for failure could have been the inexperience of 
the team performing the sentinel node biopsies.
With initial failure, the literature was searched to determine the 
methods employed by other groups to improve sentinel node retrieval 
and accuracy rates. In particular, Albertini reported that the use of
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radiocolloid injection with blue dye increased sentinel node 
identification rates from 70% to 96% in melanoma patients who 
underwent preoperative lymphoscintigraphy and the use of a hand 
held gamma probe^®®. Additionally, Morton, who first described the 
sentinel node technique, recommended the combination of blue dye 
and radiocolloid use in cutaneous head and neck melanoma sentinel 
node biopsy^despi te initially performing sentinel node biopsy using 
blue dye alone.
Accordingly, the technique used to identify the sentinel nodes in head 
and neck cancer was modified to include pre-operative radiocolloid 
injection and lymphoscintigraphy, following an application to the 
Department of Health for a certificate from the Administration of 
Radioactive Substances Approval Committee (ARSAC).
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Figure 9: Skin flap raising during a neck dissection
(original in colour)
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CHAPTER 3: CHOICE OF COLLOID IN HEAD AND 
NECK CANCER SENTINEL NODE BIOPSY
INTRODUCTION
Following the initial failure of sentinel node biopsy with blue dye 
alone, it was decided to perform sentinel node biopsy using 
additionally radiocolloid injection and lymphoscintigraphy.
Sentinel node biopsy in breast cancer and melanoma has been 
shown to be more effective and reliable when using a combination of 
blue dye and radiocolloid^®®. In particular, in head and neck 
melanoma sentinel node biopsy, where sentinel nodes are located in 
the neck, routine use of pre-operative lymphoscintigraphy and the 
intraoperative use of the hand held gamma probe leads to successful 
identification of the sentinel node^ ®®’^^® more often than when blue 
dye alone is used. Sentinel node biopsy of mucosal cancer of the 
head and neck had not been investigated with success or in a 
reasonable population group, prior to our study, and in order to 
perform the technique using radiocolloid in addition to blue dye a 
technique was developed and subsequently refined during the 
course of the period of study.
Two colloids are available for lymphoscintigraphy in the UK: Nanocoll 
and Albures^'^^ Albures has a mean diameter particle size of 500nm 
and passes slowly from the interstitium to the lymphatic vessels and 
thence to sentinel nodes, but remains within the first echelon node. 
Nanocoll has a mean diameter particle size of 80nm, passes quickly 
from interstitium to the lymphatic vessels but passes from first 
echelon node to non-sentinel nodes in the regional lymph node 
basin^^\
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In melanoma and breast cancer sentinel node biopsy (Figure 10), 
choice of colloid remains a continuing debate^^ '^^^®. In the UK and 
Europe, the choice remains between Albures and Nanocoll.
In our study of head and neck cancer sentinel node biopsy, Albures 
was chosen as the colloid to inject initially, and later in the study, 
Nanocoll was introduced to specific sub-groups of cases when initial 
results with Albures were disappointing. The aim of this part of the 
study was to develop a technique to locate and to determine which 
colloid should be used to locate sentinel nodes in the neck. The end 
point of the study was the presence or absence of radioactivity in the 
sentinel lymph nodes harvested from the neck, as this was thought to 
be a reflection of the ability of radiocolloid to pass from the 
interstitium of the injected tissue into the lymphatic vessels and 
thence the lymph nodes in the regional draining basin.
METHODS
Patients undergoing prophylactic or therapeutic neck dissections for 
oral cancers between July 1998 and March 2000 were invited to 
enter our study to perform a sentinel node biopsy in addition to a 
neck dissection.
Prior to surgery, patients were transferred from the regional Plastic 
Surgery Unit at Canniesburn Hospital and attended the Nuclear 
Medicine Department at the Glasgow Royal Infirmary for 
lymphoscintigraphy to identify regional lymph node drainage. 
Because of the distance between the two units, this was performed 
the day prior to surgery.
L y m p h o s c in t ig r a p h y
The patient was offered a local anaesthetic spray if oral pain from the 
carcinoma pre-existed, and up to 40MBq of Tc-99m-labelled Albures
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or Nanocoll was injected into the tissues surrounding the tumour, on 
both the deep and lateral aspects in an attempt to completely 
surround the tumour. Colloid was drawn up into an insulin syringe in 
a 2ml solution The patient was given a mouthwash with which to 
rinse their mouth following injection and lymphoscintigraphy 
commenced. In the first half of the study, dynamic 
lymphoscintigraphy commenced with the acquisition of 60 frames at 
15 second intervals in the anteroposterior (AP) plane. A 20% window 
centred on the 140keV photopeak was selected and the camera 
interfaced to a Bartec Micas X computing system. Either an IGE 
CamStar or IGE Maxi400A gamma camera fitted with a low energy, 
general purpose (LEGP) collimator was used (Figure 11). In the 
second half of the study, dynamic lymphoscintigraphy was 
abandoned in favour of static lymphoscintigraphy only.
Static imaging was performed on all patients both in the AP plane 
and the lateral plane. The images were acquired at 15 minutes, 30 
minutes and 60 minutes following injection of colloid or until the first 
sign of sentinel lymph nodes in the neck. Each staic 
lymphoscintigraphy image was acquired for 60 seconds. In the 
second half of the study, only static lymphoscintigraphy was 
performed. For midline tumours left and right lateral images were 
obtained and for well lateralised tumours only ipsilateral images were 
acquired unless the AP image suggested otherwise (as seen in 
Figure 12). To mark the location of the sentinel node, during static 
lymphoscintigraphy a 1cm thick lead plate was applied to the 
patient’s skin to shield the injection site from the gamma camera. The 
image was viewed on the camera’s persistence display to highlight 
radioactive nodes which were located by aligning a ®^ Co solid source 
with the hot spot in the neck. The position of the node was marked 
on the skin with indelible ink. Following image acquisition, software
58
enhancement of the image was performed by drawing a region of 
interest around the injection site. The injection site was effectively 
deleted from the image in this way and the contrast of the image 
increased to highlight sentinel nodes. A patient outline or silhouette 
was obtained either with a solid source ®^ Co pen marker (Figure 13), 
or by placing the patient between the gamma camera and a flood 
source of gamma radiation.
G a m m a  p r o b e  g u id e d  s u r g e r y
The following day during surgery, the patient was anaesthetised and 
prepared for surgery. Blue dye was injected into the same site as the 
radiocolloid (Figure 14), and the patient’s head was rotated to expose 
the side being dissected.
The Neoprobe-1500 (Neoprobe Corp, Columbus, Ohio) hand held 
gamma probe with a 14mm collimated probe was directed toward the 
previously marked radioactive sentinel node to confirm the 
approximate position of the lymph node. If necessary, the position of 
the marker was replaced to consider the effects of rotating the head.
Incisions were made to expose the neck field for a neck dissection. 
The sternocleidomastoid muscle was retracted posteriorly to reveal 
the internal jugular chain of lymph nodes and the Neoprobe was 
draped in a sterile sheath to permit its intra-operative use. The probe 
was passed along the possible anatomical positions of lymph nodes 
to identify radioactive nodes and blue staining lymphatic channels 
were followed to blue stained sentinel nodes (Figure 15).
To reduce detection of radiation scatter and shine through from the 
injection site, a sterilised 1 mm thick lead plate was used to mask the 
injection site, thus aiding in-vivo identification of radioactive nodes. 
All sentinel nodes were harvested and the Neoprobe was used to 
confirm the presence of radiocolloid within the sentinel node ex-vivo.
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Following completion of the neck dissection the specimen excised 
and the exposed neck wound were scanned with the Neoprobe to 
determine any residual radioactive nodes.
RESULTS
Between July 1998 and March 2000, 67 necks were explored for 
sentinel nodes in 62 patients undergoing elective or therapeutic neck 
dissections. Each neck was considered a single case. 40 necks were 
classified as clinically NO and 27 as clinically N+.
Injected radioactivity varied from 18MBq to 40MBq. The amount of 
activity was determined by placing the 2ml solution within an 
enclosed Geiger counter and radioactivity measured. If measured 
radioactivity was greater than 18MBq it was considered adequate to 
perform lymphoscintigraphy. All “hot spots” identified as lymph nodes 
at lymphoscintigraphy were seen within 30 minutes. In those patients 
where no nodes were seen within this time, a delayed image at 60 
minutes did not lead to the identification of a hot spot, suspicious of a 
lymph node.
T u m o u r s  o f  t h e  f l o o r  o f  m o u t h
Eighteen necks were explored for sentinel nodes for floor of mouth 
(FOM) carcinomas. Albures was used in all 18 cases. At least one 
sentinel node contained radioactivity in 14 of these 18. There were 
three cases where no hot node was found but where a blue node 
was found. There was one case where no sentinel lymph node 
(either hot or blue) was found in the neck. In summary a “hot neck” 
was found in 14 of 18 (78%) cases of carcinoma of the FOM and in 
combination with blue dye a sentinel node was found in 17 of 18 
cases.
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This chapter details our experience in performing preoperative 
lymphoscintigraphy and peroperative gamma probe directed sentinel 
node biopsy in oral SCC. During the course of our experience, we 
have aimed to refine the technique to allow easier identification of 
radioactive lymph nodes both prior to surgery in the Nuclear 
Medicine Department and during surgery. Our main initial difficulties 
were sumping and swallowing of colloid through leakage from an oral
T u m o u r s  of th e  to n g u e
Twenty-six necks were explored for sentinel nodes for clinically NO 
tongue carcinomas. Albures was used in 25 cases and Nanocoll in 
one. When Albures was used, a hot neck was found in 21 of the 25 
necks. In the four necks in which a radioactive node was absent, blue 
nodes were also absent. A "hot neck” was therefore present in 84% 
of cases and addition of blue dye did not increase the sentinel node 
retrieval rate.
T u m o u r s  o f  o t h e r  a n a t o m i c a l  s it e s
Patients with lesions other than those of the floor of mouth or tongue 
were initially injected with Albures and later, in our series, with 
Nanocoll. Albures was used in eight cases and Nanocoll was used in 
15 cases.
In the eight cases where Albures was used, a hot node was found in 
three of eight necks, no sentinel nodes were found in three and a 
blue node was found in two. In the 15 cases where Nanocoll was 
used, at least one hot node was found in 13 necks and no sentinel 
nodes (either hot or blue) were found in the other two cases. This 
difference was not statistically significant using the Mann-Witney U 
test (p=0.13)
DISCUSSION
61
ulcer, the proximity of the injection site to the neck, the choice of 
colloid, and the timing of image acquisition.
D y n a m ic  L y m p h o s c in t ig r a p h y
The images obtained from dynamic lymphoscintigraphy were 
inspected with a view to distinguishing first echelon nodes from 
second and subsequent echelon nodes. In all patients with more than 
one hot spot on lymphoscintigraphy, lymph nodes appeared 
simultaneously after injection. We therefore concluded that dynamic 
lymphoscintigraphy was an unnecessary waste of resources and 
patient time, and proceeded to perform static lymphoscintigraphy at 
15 minutes, 30 minutes and one hour post injection in two planes or 
until the appearance of radioactive nodes. In our experience hot 
spots appear 15 minutes post injection. If nodes are still absent one 
hour after injection, the lymph nodes are either too close to the 
injection site or radiocolloid has leaked out of the injection site.
If a sentinel node biopsy is to be performed as the only procedure in 
the neck in cases with absent lymphoscintigraphy nodes, it is likely 
that the surgical procedure with blue dye alone will be technically 
challenging and no sentinel node may be found.
C h o ic e  o f  C o l l o id
Choice of colloid has not been previously investigated for patients 
with oral cancers. Although the differences in colloids has been 
discussed previously, it is worth repeating here in the context of the 
reasons for choosing Albures over Nanocoll in oral cancer sentinel 
node studies. Initially the colloid used was Albures since this remains 
within the first lymph node it encounters^^®, and all radioactive nodes 
would thus be first echelon nodes. Since hot nodes were only seen 
consistently with floor of mouth and tongue lesions, our choice of 
colloid in this group of patients remains as Albures. Nanocoll is used
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for tumours at all other sites, since there was a trend towards 
increasing sensitivity of hot node identification following injection at 
these sites with the smaller diameter colloid.
The properties of the ideal colloid have been previously described. 
The ideal colloid should be a licensed product, with a narrow particle 
size range, with a 99mTc label. It should be stable on storage and be 
transported by lymphatic channels quickly to the sentinel node, 
where it should remain'"^®.
Albures is a large and slowly moving colloid with a mean particle size 
of 500nm but has the advantage of remaining in first echelon lymph 
nodes. Conversely, Nanocoll is a faster moving smaller diameter 
colloid with a mean particle size of 80nm but moves more readily 
from sentinel nodes to second and subsequent echelon nodes. The 
tongue and floor of mouth may have a higher concentration of 
terminal lymphatics^^^’^^ ® and larger diameter colloids are more likely 
to move from lymphatic vessels to sentinel nodes. If Albures is used 
in areas of low lymphatic density, the injection will remain in the 
interstitium of the injected tissue and if Nanocoll is used in the tongue 
or floor of mouth a greater number of hot nodes will be found in the 
neck, some of which will not be true first echelon nodes.
S o f t w a r e  m a s k in g
A few studies have previously highlighted the difficulties in 
performing lymphoscintigraphy in head and neck malignancies^^®'^®®. 
One of the difficulties quoted in head and neck cancer 
lymphoscintigraphy is the closeness of the injection site to the 
sentinel nodes. This prevents areas of relatively low radioactivity (for 
example sentinel nodes) from being seen in the presence of areas of 
much higher radioactivity (for example the injection site). Sentinel 
nodes sited close to the injection site are difficult to distinguish during
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lymphoscintigraphy, however, by defining a region of interest around 
the injection site, and masking the region, the areas of relatively low 
radioactivity may subsequently be seen. The process of software 
marking is shown in Figure 16.
In t r a o p e r a t iv e  l e a d  s h ie l d in g
The combination of software masking and intraoperative lead 
shielding minimises the difficulties caused by the proximity of the 
sentinel nodes to the injection site. During surgery with the gamma 
probe, a series of 1mm thick lead plates were used to surround the 
injection site, if possible. This minimises shine-through and scatter of 
radioactivity from the injection site to the neck. This is shown in 
Figure 17.
S u m p in g  a n d  s w a l l o w i n g  o f  c o l l o id
Since malignant oral lesions are commonly ulcerated, injections of 
radiocolloid (and blue dye) will easily leak through to the oral cavity. 
Although blue dye can be seen leaking from the injection site during 
surgery, unless a dye is added to the colloid, any leaked radiocolloid 
will remain unseen until imaging. We ask patients to use a 
mouthwash following injection of radiocolloid, however, if the 
pharynx, oesophagus and stomach are seen during 
lymphoscintigraphy (as seen in Figure 18) the patient is asked to 
swallow a drink. This passes much of the radiocolloid to the stomach, 
permitting successful lymphoscintigraphy in some cases.
B i l a t e r a l  n e c k  d r a in a g e
Sentinel nodes are occasionally found in both necks, especially in 
tumours that are close to, or cross, the midline. Since shine-through 
may cause confusion in interpreting lymphoscintigraphy images with 
bilateral sentinel nodes, we suggest the patient adopts an oblique 
view, laterally rotating the neck to the opposite side. Hot sentinel
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nodes from the contralateral neck appear more anterior to the 
sentinel nodes in the neck being investigated, and shine through is 
avoided.
C o n c l u s io n s
In summary, the use of nuclear medicine techniques is vital to the 
successful identification of sentinel nodes in head and neck cancer. 
Blue dye should be used in addition to radiocolloid for several 
reasons: it may provide a second method to find sentinel nodes in 
the “cold neck”; it is the means to distinguish the sentinel node from 
non-sentinel nodes which have taken up radiocolloid; finally, because 
of the differences in pharmacodynamics and pharmacokinetics of 
blue dye and radiocolloid, there may be cold blue nodes and hot pale 
nodes found In the neck, some of which may contain tumour. 
Sentinel nodes can be successfully identified during 
lymphoscintigraphy imaging but the technique can provide 
challenges to the sentinel node team.
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TABLES AND FIGURES
Figure 10: Sentinel node biopsy in the axilla
(original in colour)
Figure 11: Gamma camera and collimator used during 
lymphoscintigraphy
(original in colour)
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Figure 12: Lymphoscintigraphy image showing asymmetrical 
bilateral drainage from a centrally placed anterior floor of mouth 
tumour
», I
•5.
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Figure 13: Cobait-57 marker pen
(original in colour)
Figure 14: Blue dye injection to surround a tumour
(original in colour)
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Figure 15: Hot blue node found during a neck dissection
(original in colour)
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Figure 16: Masking of the injection site to highlight the sentinel 
nodes
(original in colour)
Image from lymphoscintigraphy before 
application of a software mask
Image from lymphoscintigraphy after 
application of a software mask (to the 
same image as above)
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Figure 17: The use of lead shields intraoperatively to prevent 
shine through from the injection site
(original in colour)
73
Figure 18: Swallowed colloid passing from mouth to stomach 
and liver
(original in colour)
Oropharynx
Oesophagus
Liver
Stomach
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CHAPTER 4: SENTINEL NODE BIOPSY PATHOLOGY 
USING RADIOCOLLOID AND BLUE DYE IN THE 
CLINICALLY NO NECK
INTRODUCTION
The sentinel node concept states that tumour spread is embolic In 
nature -  tumour metastasises in an orderly and progressive manner 
through the regional node basin and metastatic emboli will seed 
initially in the first echelon node within the basin® .^ In order to 
determine whether the concept was applicable to head and neck 
cancer, a method was required in which the first echelon node could 
be identified consistently. Having used the technique using blue dye 
alone with little success, both in terms of identifying the sentinel node 
and in terms of accurately staging the neck, the methodology was 
changed to assess the ability to identify the sentinel node in patients 
with head and neck cancer.
METHODS
Patients with oral or oropharyngeal carcinomas undergoing an 
elective neck dissection were invited to enter our study. Tumours 
were amenable to injection without the need for general anaesthesia 
and only patients whose planned primary treatment included a formal 
elective neck dissection were enrolled. Ethical approval was obtained 
from the local ethics committee prior to commencing our study.
The day prior to surgery, patients attended the Nuclear Medicine 
Department, where up to 40MBq of Tc-99m labelled colloidal human 
serum albumin -  either Nanocoll or Albures (Nycomed Amersham, 
High Wycombe, Bucks, UK) in approximately %-1 ml of saline -  was 
injected at as many points as necessary in an attempt to completely
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surround the tumour on its deep and lateral aspects. Initially, Albures 
was the colloid used in all cases, but following our initial learning 
curve, Albures, with a mean particle size of 500nm, was 
subsequently only used for primaries of the tongue and floor of 
mouth and Nanocoll, with a mean particle size of 80nm, was used for 
tumours at other sites. Static lymphoscintigraphy for 60 seconds was 
performed at 15 minutes, 30 minutes and 60 minutes following 
injection, or until the first appearance of sentinel nodes within the 
neck. During surgery, approximately 34-2 ml of Patent Blue V dye 
(Laboratoire Guerbet, Aulnay-Sous-Bois, France) was injected into 
the same site as radiocolloid, and skin flaps suitable for a neck 
dissection were raised. The sternomastoid muscle was retracted 
posteriorly to expose the deep chain of cervical lymphatics and 
attempts were made at identifying sentinel nodes. Blue stained 
lymphatics were followed to blue lymph nodes, and radioactive lymph 
nodes were identified with a Neoprobe 1500 hand held gamma probe 
(Neoprobe Corp, Ohio, USA). Sentinel nodes were identified in their 
lymph node level and were labelled according to colour and presence 
of radioactivity. Radioactivity was confirmed within the sentinel node 
ex-wVo. An appropriate neck dissection completed the surgical 
procedure. At the time of surgery, lymph node levels were marked 
with metal disks. The sentinel nodes were fixed in 10% neutral 
buffered formalin and after fixation were bisected through their 
longest axis. If the thickness of the halves was more than 2mm the 
slices were further trimmed to provide additional 2mm thick blocks. 
The remainder of the neck specimen was dissected following fixation 
and all nodes over approximately 2.5mm in maximum diameter were 
identified in their anatomic groups. Each node was bisected through 
its longest axis and one half was processed for histological 
examination. One Haematoxylin and Eos in (H&E) stained section
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was prepared from each block and was examined for the presence of 
nodal involvement by tumour.
RESULTS
Between July 1998 and March 2000, 40 necks were explored for 
sentinel nodes in 37 patients with biopsy proven squamous cell 
carcinoma. Each neck side was considered a single case. Thirty-nine 
necks were staged NO and one patient was staged clinically as Nx, 
because of palpable cervical lymphadenopathy from longstanding 
non-Hodgkin’s lymphoma. The clinical stage of the primary was T1 in 
14, T2 in 14, T3 in three and T4 in nine. The site of the primary 
squamous carcinoma was the tongue in 21, floor of mouth in ten, soft 
palate in four, retromolar trigone in three, the buccal mucosa in one 
and lower alveolus in one. The male to female ratio was 2:1. The 
mean age of patients was 59 (range 29-84).
Sentinel nodes were found in 36 of the 40 necks (90%). Ninety 
sentinel nodes were found in total. Forty-one nodes were both 
radioactive and blue (“hot blue” nodes), 35 were hot only, and 14 
were blue only. The median number of sentinel nodes per neck was 
two with a mean of 2.2 (range 0-6).
Sentinel nodes were found in lymph node levels I to V and are 
summarised in Table 7. Two sentinel nodes were found in level Mb, in 
the triangle bordered by the skull base, sternomastoid muscle and 
the spinal accessory nerve.
In the four necks where sentinel nodes were not identified one was a 
patient with a T2 anterior floor of mouth tumour undergoing bilateral 
neck dissections with palpable lymphadenopathy from SCC on one 
side of the neck and no sentinel node was identified in the uninvolved 
neck. Three were patients with well lateralised tongue carcinomas
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undergoing unilateral neck dissections. These three tongue 
carcinomas were classified as T2 in one case and T4 in two. In all 
four cases the neck dissection specimens were examined for blue 
and radioactive nodes ex~vivo, however none were found.
Two patients had areas of radioactivity, suggestive of sentinel nodes, 
identified out with the neck during lymphoscintigraphy. One patient 
had a T1 left body of tongue SCC, and the other had a T2 left soft 
palate carcinoma. In both cases, lymphoscintigraphy identified the 
left tonsillar region as the site, but tonsillectomies were not 
performed. The necks of both patients were classified as pNO.
A total of 849 lymph nodes, including sentinel nodes, was examined 
from 40 necks. A radical or modified radical neck dissection was 
performed in 22 cases, a supraomohyoid neck dissection in three, 
and a selective neck dissection excising levels l-IV in 15. In two 
cases of floor of mouth carcinomas, the planned procedure of a 
supraomohyoid neck dissection was converted to one which included 
level IV, since the sentinel nodes were located inferior to the 
omohyoid muscle and in one of these cases the sentinel node in 
level IV contained tumour. Table 8 summarises the number of lymph 
nodes examined and containing tumour from the neck dissections.
Twenty necks were pathologically staged as NO and 20 as 
pathologically N-positive (nine were pN1, eight were pN2b and three 
were pN2c). In the N-positive group (pN+), sentinel nodes were 
found in 17 and contained tumour with conventional histology in 16, 
equating to a sensitivity of 94% (95% confidence interval: 82-100%). 
In three pN+ cases no sentinel node was found and the sentinel 
node biopsy procedure was considered a technical failure. 
Accordingly, a total of 16 of 20 cases were correctly identified by the 
technique with metastasis in the sentinel node. Thus, the sensitivity 
when considered on an “intention to treat” basis, rather than by
78
considering whether the procedure was technically competent, was 
80% (16/20).
Forty-one sentinel nodes were harvested in total from the 20 pN+ 
necks, and tumour was found in 18 nodes. Table 9 summarises the 
presence of tumour, radioactivity and blue dye within all sentinel 
nodes harvested from pN+ necks.
In the 16 necks from which sentinel nodes containing tumour were 
harvested, the sentinel nodes were the only lymph nodes containing 
tumour in 12. Additional (non-sentinel) lymph nodes contained 
tumour in four necks. In three of these four necks, one additional 
lymph node was found to contain tumour and the levels of the neck in 
which sentinel and non-sentinel nodes were found, are shown in 
Table 9.
In three of four cases where sentinel nodes were not detected, the 
neck was staged pN+. In two cases, the primary tumour was a T4 
tongue carcinoma and the third was a T2 tongue tumour. One was 
staged pathologically as pN2b and two were pN I. In the case staged 
N2b, two nodes were involved with tumour, one of which was 
extensively replaced by squamous cells and showed early 
extracapsular spread. In the two cases staged as N1, early lymphatic 
spread was seen in one node and in the other case, one small 
tumour deposit of approximately 200 microns in maximum diameter 
was seen within a lymphatic channel in the nodal capsule. In these 
three cases where sentinel nodes were not identified and the neck 
contained metastasis, lymphoscintigraphy images were examined. In 
two cases, no hot spots were seen and in one patient a single hot 
spot was seen in level I from a patient with a tongue tumour. Two 
pathologically involved nodes were identified in this patient in level II.
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Twenty cases were staged pathologically as pNO and a sentinel node 
was found in 19. In these cases, the sentinel node did not contain 
tumour, by definition.
There was one “false negative” sentinel node, in a patient with an 
extensive T4 SCC of the floor of mouth in whom negative sentinel 
nodes were found in levels I and II, and tumour was found within a 
“non-sentinel” level II node. In this case, a sentinel node was found, 
and the procedure considered a technical success, hence we 
considered this to be an indisputable false negative result.
DISCUSSION
This study was performed to determine if the sentinel node concept 
was valid for head and neck squamous cell carcinoma in necks with 
impalpable métastasés undergoing elective neck dissections. We 
conclude that the sentinel node, when identified, using a combination 
of the hand held gamma probe and blue dye visualization, reflects 
the positivity or negativity of the neck with a high degree of accuracy. 
We found that sentinel node pathology using conventional H&E 
stains reflected that of the neck dissection in 94% of cases with 
impalpable disease, when the SLN was found.
There were four cases (10%) where the sentinel node was not 
identified. If no sentinel node is found in the neck, the procedure is 
considered a technical failure and the sentinel node procedure 
cannot be considered a reliable technique. In our series, three of the 
four cases of sentinel node biopsy technical failure revealed lymph 
nodes in the neck dissection specimen containing metastasis (75%). 
If a sentinel node procedure is planned for a patient, and no sentinel 
node identified, an elective neck dissection should be strongly 
considered as an alternative.
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Sentinel node biopsy is technically challenging and difficulties with 
identifying sentinel nodes may be encountered during 
lymphoscintigraphy and surgery. Sentinel nodes may be too close to 
the primary injection site to be discernible by the gamma camera and 
this is particularly troublesome for sentinel nodes in level I for a 
primary located in the floor of mouth. Although the use of lead shields 
and software masking may highlight level I sentinel nodes, if the 
procedure is to find a role in the management of the clinically NO 
neck for floor of mouth lesions, we would recommend exploration of 
level I in all cases where the primary is located in the floor of mouth. 
During surgical exploration of level I, the hand held gamma probe will 
detect scatter and shine-through from the primary site; the use of 
sterilized lead plates will aid in isolating radioactivity from lymph 
nodes. Blue dye visualisation may be the primary means of 
identifying nodes in level I, with the hand held probe being used to 
confirm the presence of radiocolloid within the node ex-vivo. Lastly, 
removal of the primary does not remove all radioactivity from the 
injection site, despite adequate tumour resection margins, although 
the reduction in radioactivity within the primary site can aid in the 
subsequent identification of hot nodes close to the primary.
Both blue dye and radiocolloid are required for sentinel node biopsy 
to be successful. Two sentinel nodes containing tumour were blue 
but contained no radiocolloid and six sentinel nodes containing 
tumour were hot but had no blue dye within them. In finding the blue 
nodes, pre-operative lymphoscintigraphy aided in localizing the 
presence of blue dye. Since the pharmacodynamics of blue dye will 
be different from radiocolloid, it is not surprising that some sentinel 
nodes are identified with one modality or the other.
Sentinel nodes have been identified in clinically unpredictable sites. 
This is a similar finding to that in melanoma and breast cancer
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sentinel node b i o p s y ^ T r a d i t i o n a l  anatomical teaching from 
cadaveric studies has suggested that lymph drainage may be 
sequential from level I to the upper jugular chain and thence to the 
lower jugular chain. This has given rise to the misconception of "skip 
métastasés”^ where tumour métastasés by-pass upper lymph 
nodes in levels I and II and are found in lower levels. If the 
anatomical location of sentinel nodes is a reflection of direct 
lymphatic drainage, the findings that sentinel nodes may be located 
at various levels in the neck indicates that tumour drainage is 
dependent on individual anatomical pathways in some cases.
In most cases, sentinel nodes have been the only lymph nodes with 
tumour in the involved neck (12/16 cases). This is similar to the 
experience of those performing sentinel node biopsy for breast 
cancer and melanoma^® '^^®®. When non sentinel nodes are also 
involved with tumour, these have occasionally been identified at 
higher anatomical levels in the neck. This phenomenon may be a 
reflection of tumour spread from the sentinel node to a second 
echelon node at a higher anatomical level.
In one case of a patient with long standing cervical lymphadenopathy 
from a low grade non-Hodgkin’s lymphoma, the neck was staged 
clinically Nx. The primary was a T 1 lateral tongue carcinoma, and the 
neck was found to contain squamous cell carcinoma in three nodes 
in levels II, III and IV. Three sentinel nodes were found in levels III 
and IV, with one of the two “cold blue” nodes from level IV contained 
tumour. Despite the presence of palpable lymphadenopathy from a 
different pathological process, sentinel node biopsy correctly 
identified nodal disease from the squamous cell carcinoma. In such 
cases, lymph nodes with increased hydrostatic pressure may divert 
lymphatic flow, so that sentinel nodes are found at clinically aberrant
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locations, in these cases, the sentinel node location may reflect the 
true anatomic drainage pathway of the primary site.
On average, more than one sentinel node will be found in a single 
neck. In cutaneous melanoma sentinel node biopsy, approximately 
two-thirds of patients will have one sentinel node, one-quarter will 
have two sentinel nodes and the remainder will have three or more 
sentinel nodes^ ®®. Since the oral cavity has a rich plexus of lymphatic 
vessels, these findings may reflect the diverse lymphatic drainage 
pathways to the neck.
Sentinel nodes were not found in four cases. One of the cases was a 
neck from a patient undergoing bilateral neck dissections for a 
tumour close to the midline. The lack of sentinel nodes on the 
contralateral neck was most likely a reflection of the true drainage 
pattern of the tumour. The remaining cases were tongue tumours; in 
all cases, the tumours were indurated and ulcerated. Blue dye was 
seen to leak out of the injection site into the oral cavity at the time of 
surgery. We presume the colourless injected colloid followed the 
same pathway, preventing lymphatic uptake of both dye and 
radioactivity. In three of the four cases where sentinel nodes were 
not identified, the neck dissection specimen was found to contain 
tumour. If sentinel node biopsy finds a role in the management of the 
clinically NO neck, then in cases where a sentinel node is not 
identified a formal elective neck dissection should be considered for 
staging purposes -  similar recommendations are made for the 
absence of detectable sentinel nodes in breast cancer c a s e s . I n  
those cases where sentinel nodes were not identified, the procedure 
was considered a failure. The sensitivity of the sentinel node 
procedure was 94% when successful; however, if all cases are 
considered on an Intention-to-treat basis, where the sentinel node 
procedure has been considered a technical failure, then the
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sensitivity of the procedure falls to 80% (16/20 compared with 16/17). 
These results are similar to the failure rate of approximately 5% seen 
following a SOHND^°\ in those cases where the SOHND procedure 
has been deemed a technical success.
Sentinel node pathology did not reflect that of the remaining neck 
dissection in one case of successful “sentinel” node biopsy. There 
was, thus, one false negative sentinel node. In this case, the patient 
had an extensive T4 tumour of the floor of mouth, invading into the 
tongue, mandible and skin. In this case, the injection site of colloid 
and dye was not at the metastasising edge of the tumour, since the 
small volume of injection was insufficient to completely surround the 
tumour on its deep and lateral aspects. If sentinel node biopsy is to 
be used as a staging tool for head and neck cancers, it is important 
to inject around the whole tumour periphery.
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CONCLUSIONS
In conclusion, the sentinel node concept appears to be valid in head 
and neck cancer. Patients with small carcinomas of the upper 
aerodigestive tract that are accessible to injection without the need 
for general anaesthesia may potentially undergo sentinel node 
localisation to stage the neck with a high degree of accuracy. 
Although there are technical limitations to the procedure and 
harvesting of the node can occasionally be challenging, the 
procedure is worth investigating as a tool to upstage the clinically NO 
neck. A study was therefore started to perform sentinel node biopsy 
in patients who would otherwise undergo regular observation of their 
neck only. In the study, patients would undergo sentinel node biopsy 
and appropriate treatment to their primary lesion. If the sentinel node 
was found to contain tumour métastasés, the patient would 
subsequently undergo a therapeutic modified radical neck dissection. 
Details of the initial results from this study are presented in Chapter 
9.
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TABLES AND FIGURES
Table 7: Number of sentinel nodes found by lymph node level 
and involvement by SCC
Lymph node level Number of sentinel 
nodes
Number of sentinel 
nodes containing 
tumour
1 13 3
II 50 10
III 22 3
IV 4 2
V 1 0
Table 8: Number of lymph nodes examined and containing 
tumour by lymph node level
Lymph node level Number of nodes 
examined
Number of nodes 
containing tumour
Level 1 148 7
Level II 261 16
Level III 188 4
Level IV 170 2
Level V 94 0
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Table 9: Sentinel nodes in the pN+ neck according to presence 
of tumour, dye and radiocolloid
nodes with 
tumour
nodes without tumour Total
Hot Blue 10 11 21
Hot only 6 9 15
Blue only 2 3 5
Total 18 23 41
Table 10: The anatomical location of non-sentinel nodes 
containing tumour, when non-sentinel nodes were found to 
harbour métastasés
Level of sentinel node containing 
tumour
Level of non sentinel node in same 
neck with tumour
II II
II 1
III II
IV II, III
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CHAPTER 5: SENTINEL NODE BIOPSY PATHOLOGY 
USING BLUE DYE AND RADIOCOLLOID IN THE 
CLINICALLY INVOLVED NECK
INTRODUCTION
One of the concerns of sentinel node biopsy is that lymph nodes 
grossly involved with tumour will not take up either blue dye or 
radiocolloid^°^. These grossly involved nodes may have been the first 
echelon nodes to which tumour had initially metastasised but are no 
longer the "sentinel nodes” identified by blue dye or radiocolloid. If 
blue dye and radiocolloid are diverted to un involved lymph nodes, a 
biopsy of such a radioactive or blue node would be misleading and 
inappropriate. In these cases, it is thought that the hydrostatic 
pressure within involved nodes diverts lymphatic fluid to nearby 
nodes that are uninvolved with tumour. Recently, however, in a group 
of patients with melanoma, it was shown that the sentinel node 
biopsy technique was valid in patients with grossly involved lymph 
nodes, and the sentinel node did indeed contain tumour, albeit in a 
limited number of cases^°^.
This part of the study was performed to investigate whether the 
sentinel node concept was valid in patients with head and neck 
cancer and palpable lymphadenopathy. Approximately 10% of 
patients with palpable cervical lymphadenopathy have no tumour 
métastasés and the lymphadenopathy is from another cause^ "^ ,^ 
however these patients are still staged as Since there is a well 
recognised learning curve for sentinel node biopsy in melanoma and 
breast cancer sentinel node b i o p s y ^ a n d  a possibly longer 
learning curve for head and neck cancer, performing the procedure 
on patients undergoing therapeutic neck dissection may also aid in
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the learning process. In addition, the study was performed to 
determine if the choice of colloid used for lymphoscintigraphy and 
radioguided surgery determined the accuracy of the procedure in 
identifying involved nodes.
Finally, if sentinel node biopsy is to find a role in the management of 
the neck in patients with head and neck cancer, its limitations should 
be defined. If the procedure is limited by the overt presence of nodal 
métastasés, then this should be realised prior to formal studies to 
evaluate the procedure as a staging tool in clinical trials.
METHODS
Between July 1998 and March 2000, patients with squamous cell 
carcinoma of the upper aerodigestive tract, undergoing therapeutic 
neck dissections were enrolled. Ethical approval from the local ethics 
committee and an ARSAC certificate from the Department of Health 
was granted prior to starting the study. Each neck side from a patient 
with palpable lymphadenopathy was considered a single case.
Patients underwent lymphoscintigraphy prior to surgery. Up to 40 
MBq (mean 30 MBq, range 18-40MBq) of radiocolloid was injected at 
the deep and lateral aspects of the primary tumour or its site of 
previous excision to completely surround the tumour or scar. Patients 
were asked to rinse their mouth immediately following injection to 
prevent sumping and swallowing of the colloid. A one minute static 
lymphoscintigraphy image was obtained at 15 minute intervals post 
injection in the anteroposterior and lateral planes until identification of 
the first hot spot within the neck, or for up to one hour. In the first 
year of the study, patients were injected with Albures (Nycomed 
Amersham, Buckinghamshire, UK), and from August 1999 -  March 
2000 the radiocolloid used was Nanocoll (Nycomed Amersham, 
Buckinghamshire, UK).
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During surgery, 2ml of Patent Blue V dye (Laboratoire Guerbet, 
Aulnay-Sous-Bois, France) was injected at the same sites as 
radiocolloid. The neck dissection proceeded and if blue stained 
lymphatics were seen, these were followed to blue lymph nodes and 
their position marked. Following excision of the neck dissection 
specimen, radioactive nodes were identified with a hand held gamma 
probe (Neoprobe 1500, Neoprobe Corp., Columbus, Ohio, USA). The 
neck was scanned with the gamma probe ex-vivo after dissection of 
the neck to maintain oncological safety and prevent inadvertent 
spillage of tumour from potentially neoplastic lymph nodes. 
Radioactive and blue nodes were dissected free from the specimen 
and were labelled as “sentinel”. The anatomical level within the neck 
was noted as was the colour (blue or pale) and radioactivity (hot or 
cold). Neck dissection levels were marked on the specimen with 
metal discs and all specimens were fixed in 10% formalin.
“Sentinel” nodes were bisected through the hilum, if identifiable, or 
long axis. If the thickness of the two halves exceeded 2mm, further 
sections were taken at 2mm intervals to provide additional blocks. 
The remainder of the neck specimen was dissected and all nodes 
with a maximum diameter greater than approximately 2.5mm were 
identified in their anatomical levels. Each node was bisected through 
the hilum and one half was processed for histological examination. 
One H&E stained section was prepared from each block and was 
examined for the presence of nodal involvement by tumour.
RESULTS
Twenty seven necks were explored for “sentinel” nodes. Between 
June 1998 and May 1999 18 necks were explored in 17 patients 
injected with Albures and between June 1999 and March 2000, nine 
necks were explored in eight patients injected with Nanocoll. One
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patient from each group underwent bilateral neck dissections for 
suspected metastatic lymphadenopathy. The mean age of patients 
was 61 (range 48-87) and the male: female ratio was 25:2. The type 
of neck dissection performed was a modified radical neck dissection 
in 19, a radical neck dissection in four and a selective neck 
dissection in four.
Five cases were T1 tumours, eight were T2, two were T3, seven 
were T4 and five were classified as Tx, for patients undergoing 
metachronous neck dissection after previous treatment for their 
primary tumour. Six necks were pathologically clear of tumour (pNO) 
and 21 were found to contain métastasés (pN+) in at least one lymph 
node (78%).
A “sentinel” node was found in 23 of 27 necks. In the group injected 
with Albures a node was found in 15 of 18 cases and in the group 
injected with Nanocoll, a node was found in eight of nine cases, in 
the four cases where a sentinel node was absent, three were injected 
with Albures and one with Nanocoll. The latter case was 
subsequently found to be a pNO neck from a primary midline tumour 
of the soft palate. The primary site of the three cases injected with 
Albures was the right mandible in one case (pT4N2b), right tongue in 
one case (pTxNI) and right buccal mucosa in one (pT4N2b). 
Lymphoscintigraphy failed to identify any radioactive nodes in these 
four cases.
When Albures was used, 27 "sentinel” nodes were harvested from 15 
necks in which a node was found (mean per case: 1.8). When 
Nanocoll was used, 19 “sentinel” nodes were harvested from eight 
necks in which a node was found (mean per case 2.4). The presence 
of radioactivity and presence of blue dye in the 23 cases where a 
“sentinel” node was found is shown in Table 11.
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In 23 cases, where a “sentinel” node was found, the neck contained 
tumour in 21. When using Albures, a “sentinel” node contained 
tumour in only two of 12 cases (14%, 95% C.l. 0-35%). When using 
Nanocoll, “sentinel” nodes contained tumour in six of seven cases 
(86%, 95% C.l. 51-100%).
DISCUSSION
This study was performed to determine if the sentinel node concept 
was valid for patients with clinically involved nodes in head and neck 
cancer. In those patients injected with Albures, the radioactive or 
blue nodes did not reflect the lymph node status of the grossly 
involved neck. Large diameter colloids, such as Albures, appear to 
be diverted away from the first echelon node to uninvolved lymph 
nodes elsewhere in the neck^°^. It is likely that the large particles are 
unable to overcome the high hydrostatic pressure within grossly 
metastatic lymph nodes to enter the lymph node or be taken up by 
the antigen presenting cells within the nodes^^®. Even if there were 
blue sentinel nodes that contained tumour, but which were not seen, 
identification of the approximate position of sentinel nodes using 
preoperative lymphoscintigraphy is a prerequisite to successful 
sentinel node biopsy in head and neck cancer, in our experience^°^. 
If the radioactive nodes are not in the close vicinity of blue first 
echelon nodes, containing tumour, blue stained lymphatics and 
nodes will not be seen. The successful identification of first echelon 
lymph nodes by radiocolloid is thus important when applying the 
sentinel node concept to patients with head and neck cancer.
In those patients injected with Nanocoll, the sentinel nodes were 
more likely to contain tumour and this is an interesting finding. In our 
series, Nanocoll-guided sentinel node biopsy correctly identified 
tumour in six of seven cases. In the single case where Nanocoll
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failed to identify a radioactive or blue node with tumour, the neck was 
classified as pN1, the involved node was found in level II and 
contained extracapsular spread. The “sentinel” nodes in this case 
were found in levels I and III, both were radioactive, and the level I 
node was additionally blue. In this case, radiocolloid was most likely 
diverted from the true sentinel node to lymph nodes free from 
tumour. There was also the possibility that small deposits of tumour 
were present in these “sentinel” nodes, but were not seen as a result 
of pathological sampling error, however, this has not been further 
investigated.
In view of the limited accuracy of the technique in the clinically and 
pathologically involved neck, there appears to be no role for sentinel 
node biopsy in the clinically node positive neck. Sentinel node 
pathology does not reflect the pathological status of the lymph nodes 
within the neck with a high degree of accuracy, even when using 
Nanocoll, since the lower 95% confidence interval was only 51%. 
Although this may be a reflection of our low number of cases, it is 
unlikely that patients with palpable lymphadenopathy will undergo a 
sentinel node biopsy instead of a therapeutic neck dissection, with a 
decision to perform a neck dissection based upon the histology of the 
sentinel node.
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TABLES AND FIGURES
Table 11: Sentinel nodes by colour and radioactivity
Albures Nanocoll Total
Cold blue 8 1 9
Hot pale 15 13 28
Hot blue 4 5 9
Total 27 19 46
No. of cases n=15 n-8 n=23
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CHAPTER 8: SENTINEL NODE BIOPSY IN HEAD AND 
NECK MUCOSAL MELANOMA
INTRODUCTION
Sentinel node biopsy has emerged as an accurate method for 
determining the presence or absence of nodal métastasés in the 
management of patients with cutaneous malignant melanoma^^^'Zio- 
213. The technique involves the injection of a blue dye and 
radiocolloid, either alone or in combination, at the site of the tumour 
or its excision biopsy. These are traced to the first draining lymph 
node which is termed the sentinel lymph node and is harvested for 
detailed histological examination. A sentinel node free of tumour is 
likely to indicate the absence of nodal métastasés elsewhere in the 
regional lymph node basin® .^ Although the technique using a tracer to 
identify the sentinel node was originally described for cutaneous 
malignant melanoma®^, it is now being applied to different 
malignancies and initial results in patients with breast cancer2i" '^2i7 
and head and neck squamous cell carcinoma^^ '^ i^B-zzo 
encouraging.
Oral cavity malignant melanoma is relatively rare^^i. it spreads via 
lymphatics to the regional lymph nodes in the neck and knowledge of 
the presence or absence of nodal métastasés affects management. 
Patients with known nodal disease are treated more aggressively, 
however, the management of the clinically negative neck in oral 
malignant melanoma Is the subject of surgical controversy^^^-z^^
This paper describes the use of sentinel node biopsy in two patients 
with oropharyngeal melanomas and clinically disease free necks, 
who underwent excision of the primary tumour and sentinel node 
biopsy.
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METHODS
Two patients were studied as part of larger trials of sentinel node 
biopsy in oral malignancies. Both patients were entered into different 
ethically approved trials. The first patient presented with a tongue 
melanoma and the second with a palatal melanoma.
Case 1 : Tongue melanoma
A 47 year old male presented with an area of pigmentation of the left 
side of his tongue, approximately 1.5cm in diameter. Figure 19 
shows the lesion in the patient.
An incisional biopsy confirmed the diagnosis of invasive melanoma 
and a decision was made to excise the lesion and perform an 
ipsilateral type 3 modified radical neck dissection at the same time. 
Flis cervical nodes were palpably clear of métastasés. He agreed to 
enter our study of sentinel node biopsy on patients with oral 
malignancies undergoing neck dissections as part of the primary 
treatment for their lesions. Preoperative lymphoscintigraphy was 
performed by injecting 35MBq of 99m-technetium labelled colloidal 
albumin with a large mean particle diameter (Albures) into the tongue 
around the melanoma to completely surround the tumour. 
Subsequent scintigraphy images, obtained with an IGE Maxi 400A 
gamma camera fitted with a low energy general purpose collimator 
demonstrated drainage to both sides of the neck (Figure 20) and the 
positions of the lymph nodes were marked on the skin with indelible 
ink.
The presence of aberrant sites of sentinel nodes was discussed with 
the patient, and it was decided to continue with a neck dissection on 
the left but to include sentinel node biopsies on the right. During 
surgery, 1m! of Patent Blue V dye was injected into the same site as 
Albures. A tri-rad I ate incision was made on the left side of the neck,
96
sternomastoid was retracted posteriorly and the sentinel nodes were 
harvested using a combination of following blue stained lymphatics to 
blue stained lymph nodes and localisation with the Neoprobe-1500 
(Neoprobe Corp, Dublin, Ohio) hand held gamma probe. One blue 
stained radioactive node and two pale but radioactive nodes were 
retrieved. On the right side, a smaller incision was made overlying 
the sentinel nodes, sternomastoid was retracted posteriorly to 
expose the deep cervical chain of lymph nodes and three pale- 
radioactive sentinel nodes were harvested. A neck dissection on the 
left side completed his surgical procedure.
Case 2: Palatal melanoma
A 64 year old lady presented with an area of diffuse melanosis on the 
hard palate, extending to the soft palate (Figure 21).
An incisional biopsy confirmed the presence of invasive melanoma 
and a decision was made to excise the entire palatal mucosa and 
reconstruct the defect with a skin graft. Fler cervical nodes were 
palpably clear of tumour. She agreed to enter our interventional study 
of sentinel node biopsy on patients with oral malignancies who would 
not otherwise undergo staging neck surgery. Preoperative 
lymphoscintigraphy was performed by injecting 35MBq of 99m- 
technetium labelled colloidal albumin with a small mean particle 
diameter (Nanocoll) into the normal mucosa and submucosa 
surrounding the tumour at four points around the area of diffuse 
melanosis. Subsequent lymphoscintigraphy demonstrated a single 
area of radioactivity in the right side of the neck in the submandibular 
region (Figure 22).
During surgery, blue dye was not injected, since it was felt that blue 
staining of the palatal mucosa would compromise the oncological 
safety of the excision. A skin crease incision was made to identify
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and harvest a single radioactive sentinel lymph node in level one, 
immediately deep to the right submandibular gland.
RESULTS
Case 1: Tongue Melanoma
Three sentinel nodes were harvested from the left side and three 
sentinel nodes were harvested from the right. All sentinel nodes were 
free of tumour by both conventional and immunohistochemical stains. 
A further 12 non-sentinel nodes from the left neck dissection 
specimen were examined and none contained tumour. The tumour 
had a maximum diameter of 1.5 cm and a depth of 1.35 mm. The 
patient continues to be followed-up every three months initially, and 
twelve months following surgery, remains free of locally invasive or 
regional metastatic melanoma.
Case 2: Palatal melanoma
One sentinel node was harvested from the right submandibular group 
of nodes, and was visibly pigmented at the time of surgery. 
Histological examination revealed the presence of iron pigment, in 
the form of haemosiderin, and melanin within macrophages, though 
no melanocytes were easily identifiable. Examination of the primary 
site confirmed an invasive component through the full thickness of 
mucosa but not invading maxilla. Since the node was located on the 
right side from a midline tumour, the patient subsequently underwent 
a right sided neck dissection in which a further seven lymph nodes 
were excised and none contained melanoma.
DISCUSSION
This chapter describes the management of two patients with oral 
cavity melanoma, in whom sentinel node biopsies were performed to
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predict their nodal status. Although sentinel node biopsy has been 
previously described for cutaneous malignant melanoma and oral 
squamous cell carcinoma, to our knowiedge it has not been 
previously described for use in oral cavity maiignant melanoma.
Sentinel nodes were harvested in both patients from clinically 
unpredictable sites, in the case of the tongue melanoma, although 
the lesion was well laterallsed and situated on the anterior tongue, 
lymphatic drainage was demonstrated in both sides of the neck. In 
the case of the palatal melanoma, injection of radiocolloid was 
directed at four points to surround the lateral margins of the 
melanosis and a single sentinel node was found in the right 
submandibular triangle. In addition, the invasive component of the 
melanoma was located in the mucosa of the left palate, yet the 
sentinel node in the right neck contained melanin pigment, which 
presumably originated from the melanoma. Melanin is not normally 
found in lymph nodes and the most likely explanation for this 
phenomenon is that some of the macrophages from the lamina 
propria area associated with the melanoma migrated to the lymph 
node after melanin uptake following the initial biopsy.
Since sentinel lymph nodes have been found in unpredictable sites 
for patients with cutaneous meianoma^^"^’^ ^^ ’ ®^"^ ’ ®^®'^ ®®’^ ®^, it is perhaps 
not unexpected that unusual patterns of lymphatic drainage were 
seen in our two cases. We assume that the locations of the sentinel 
nodes reflected the true lymphatic drainage of the tumours. Without 
the benefit of pre-operative lymphoscintigraphy, prophylactic lymph 
node dissections would have been misdirected, to the left neck in the 
case of the tongue melanoma and both neck sides in the case of the 
palatal melanoma.
The management of the clinically negative neck in oropharyngeal 
malignant melanoma is subject of surgical controversy. The condition
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is relatively rare, neck métastasés are a common feature, with 
approximately 30% of patients harbouring nodai disease and there is 
no consensus of opinion regarding the optimal management of the 
clinically NO neck^ "^ .^ Although staging neck dissections may be 
performed to determine the presence of nodal disease, they are not 
without potential complications and bilateral neck dissections carry 
greater morbidity than unilateral surgery^^®"^^^
The tongue is an uncommon site for malignant melanoma, and little 
is known of its natural history^^ '^ "^^®. Our experience with tongue 
squamous cell carcinoma suggests that an aggressive approach to 
the neck is warranted, even for relatively early stage disease^® but it 
is not known whether melanoma of the tongue carries a high rate of 
subclinical nodal disease and whether the prognosis is worse than 
melanomas of other sites within the oral cavity, as is the case with 
tongue squamous cell carcinoma. In the management of our patient 
with early tongue melanoma, the advantages and disadvantages of a 
staging neck dissection were discussed pre-operatively, and a joint 
decision was made with the patient to perform a left sided neck 
dissection. Following the discovery of sentinel nodes in the 
contralateral neck during pre-operative lymphoscintigraphy, a further 
joint decision with the patient was made to perform selective 
lymphadenectomies of the sentinel nodes from the right neck.
Although it is unclear whether regional lymph node métastasés 
significantly alters prognosis in oral cavity melanoma^^"^, it may be 
that earlier treatment of involved lymph nodes confers a survival 
benefit. Should this be the case then sentinel node biopsy may prove 
to be a useful means of determining the nodal stage of patients with 
oral melanoma. In addition, sentinel node biopsy may be an 
alternative to a unilateral or bilateral staging neck dissection, thereby 
avoiding the associated morbidity of the procedure. Also, because of
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the variability of lymphatic drainage within the oral cavity, elective 
lymph node dissection of the most iikely involved lymph node group 
may not remove the correct nodal groups for accurate disease 
staging.
Although our experience is limited to these two cases, our early 
experiences show that sentinel node biopsy is technically possible to 
perform in oral cavity melanoma. This is aided by our experience in 
performing sentinel node biopsy for patients with oral cavity 
squamous cell carcinoma. Clearly, larger multicentre studies are 
required to further evaluate the procedure as a management option 
in clinically node negative patients with melanoma of the oral cavity.
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TABLES AND FIGURES
Figure 19: Tongue melanoma
(original in colour)
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Figure 20: Lymphoscintigraphy of patient with tongue 
melanoma showing bilateral drainage
(original in colour)
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Figure 21: Palatal melanoma with invasive component to the left 
of the midline
(original in colour)
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Figure 22: Lymphoscintigraphy of patient with palatal melanoma
(original in colour)
,\ .r
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CHAPTER 7: SENTINEL NODE DIMENSIONS AND 
QUANTIFICATION OF RADIOACTIVITY WITHIN THE 
SENTINEL NODE
INTRODUCTION
The sentinel node is the first lymph node that receives iymphatic 
drainage from a tumour iocated at a particular anatomical site® .^ One 
of the controversies surrounding sentinei node biopsy is whether all 
nodes identified as “sentinei” by radiocolloid should be excised as 
true sentinel nodes^'^^ Since some colloids move from sentinel node 
to lymph nodes lower in the draining lymphatic basin’'^ ®, if all 
radioactive nodes are excised then in some cases second and 
subsequent echelon nodes will be harvested as “sentinel nodes”. 
One of the uses of blue dye in the sentinel node biopsy procedure is 
to distinguish first echeion nodes from non sentinel radioactive 
nodes "^^ ,^ thus some radioactive nodes should remain within the 
lymph node basin, since they are not the first echelon nodes. In 
melanoma sentinel node biopsy, little information is gained by 
foliowing the radiotracer more distai to the primary site and removing 
more than two sentinel nodes "^^ .^
Since this study has shown that sentinel lymph nodes can be located 
in levels l-IV in the neck for oral cavity tumours, it is not possible to 
determine whether a blue or radioactive node is truly first echelon by 
mere location. For example, a node highlighted by radiocolloid in 
level IV is as likely to be the first echelon node as is a lymph node in 
level II. Anatomically lower nodes are not necessarily second 
echelon nodes, unless efferent lymphatics can be seen draining from 
a node at a higher level to one in a lower level and these efferents 
are usually seen with Patent Blue V dye.
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In head and neck cancer sentinel node biopsy, if several nodes are 
required to be removed from several lymph node levels, the 
complexity of the procedure may approach that of a limited selective 
neck dissection. Large lymph nodes are more likely to contain tumour 
than small lymph nodes and if only lymph nodes that are large and 
highly radioactive should be sampled as sentinel nodes, this may 
ease the complexity of the procedure, the operating time and 
pathology cost. Conversely, if lymph nodes with low amounts of 
radioactivity within them are found to contain tumour, then it is 
important that these nodes are removed during the sentinel node 
procedure.
This section of the study was performed on the cases ai read y 
outlined. The study was performed to determine if the size and 
amount of radioactivity within sentinel nodes was an indicator of the 
likelihood of nodai métastasés. Although the actual amount of 
radioactivity within a sentinel node can only be estimated with a hand 
held gamma probe, such as the Neoprobe, this was sufficient for the 
purposes of this study, since the hand held gamma probe is used 
ciinically to determine both whether nodes are radioactive and 
whether these nodes are highly radioactive or only slightly 
radioactive.
METHODS
Sentinel nodes were harvested from patients with clinically NO necks, 
undergoing neck dissection, using the procedure described in 
Chapter 3. Radioactive sentinel nodes were placed against the tip of 
the 14mm collimated probe of the Neoprobe-1500 and a 10 second 
count was made to estimate the amount of radioactivity in the 
sentinel node. Figure 23 shows the Neoprobe confirming the 
presence of radioactivity in a sentinel node ex-vivo.
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A 10 second count of estimated radioactivity was also made of the 
primary site of the tumour. Radioactive sentinel nodes were fixed in 
formalin and the dimensions of the node measured in millimetres 
(mm). Three measurements were taken of the node: the maximum 
diameter, the middle diameter and the minimum diameter. The 
volume of the lymph node was calculated using the formula: volume 
(in mm^) = %  (ti ri rz rs), where n, rz and rg were the radii of the three 
dimensions of the sentinel node. Lymph nodes were bisected, and if 
the two halves were thicker than 2mm, further sections were 
processed at 2mm intervals. A single block from each section was 
examined using Haematoxylin and Eosin stain for the presence of 
tumour within the sentinei node. The presence of tumour within the 
sentinel node was correlated with the dimensions and volume of the 
sentinel node. Only radioactive nodes were examined in the study. If 
sentinel nodes were blue but not radioactive, they were not included 
in the results of this section. Statistical significance was assumed for 
the probability that the differences were seen by chance was less 
than or equal to 5% (p < 0.05).
The exact time of the injection and the exact time of the sentinel 
node harvesting was not recorded. However, all cases were injected 
with radioactivity the afternoon before surgery and all neck 
dissections were compieted between 20 and 24 hours following 
injection.
RESULTS
Thirty-four necks were identified in which a hot node was found. A 
totai of 76 sentinel nodes were found to be radioactive, of which 35 
were hot only and 41 were hot and blue. Tumour was identified in 16 
of 76 nodes (positive nodes), and the remaining 60 nodes were free 
from overt tumour (negative nodes). One hot node was found in 14
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cases, two hot nodes were found in eight, three hot nodes were 
found in six, four hot nodes were found in three, five hot nodes were 
found in one and six hot nodes were found in two.
The maximum diameter of lymph nodes varied from 3 mm to 40 mm 
and the mean maximum diameter was 12.7 mm (95% C.I.: 11.0 -  
14.3 mm). The volume of sentinel nodes varied from 3 mm^ to 6409 
mm^ and the mean volume was 457 mm^ (95% C.I.: 249 -  664 mm^). 
The mean minimum and mean middle diameter of sentinel nodes 
was 5.2 mm and 7.4 mm respectively.
Figure 24 shows the maximum diameter of lymph nodes and the 
number of nodes with this maximum diameter.
Lymph nodes that contained tumour had a greater maximum 
diameter than non metastatic sentinel nodes, as seen in Figure 25 
and Figure 26. The mean maximum diameter of positive nodes was 
18 mm (range 7 - 4 0  mm; 95% C.l. of mean: 13.4 -  22.3 mm) and 
that for negative nodes was 11 mm (range 3 - 3 4  mm; 95% C.l. of 
mean: 9.7 -  12.8 mm). This difference was highly statistically 
significant (p=0.001), using the T-test. A box-plot of the results is 
shown in Figure 25.
Figure 26 shows the distribution of maximum diameters of positive 
and negative sentinel nodes.
When comparing middle diameters of sentinel nodes for positive and 
negative sentinel nodes, the mean of the middle nodal dimension 
was 9.5 mm and 6.8 mm, respectively. This difference was also 
significant (p=0.05) using the T-test.
Flowever, when comparing the minimum diameter and the voiume of 
sentinel nodes for positive and negative nodes, the differences were 
not statistically significant. The mean minimum diameter for positive 
and negative nodes was 6.3 mm and 4.9 mm, respectively, (p=0.07)
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and the mean volume for positive and negative sentinel nodes was 
789 mm^ and 368 mm^, respectively, (p=0.1). Even though the 
difference in the latter analysis was large, it was not statistically 
significant.
In those patients with positive sentinel nodes, the hottest nodes were 
not always the nodes that contained tumour. Table 12 shows the 
nodes (ranging from the hottest to coldest radioactive nodes per 
patient) and examines their pathology. There were two patients with 
more than one positive sentinei node, in these two, the 2'^  ^ and 4^  ^
hottest nodes and the and 4*^  hottest nodes contained tumour, in 
the rest of the 16 sentinel nodes that contained tumour, no more than 
one node per patient contained métastasés. In 9 of 16 cases, the 
hottest node contained métastasés and in 5 cases, the hottest 
sentinel node did not contain tumour despite the presence of tumour 
in another radioactive sentinel node. All patients would have been 
staged accurately if only the hottest three sentinel nodes had been 
retrieved.
The node with the largest maximum diameter was not always the 
sentinel node that contained métastasés. Table 13 shows that 
although in 12 cases the node with the largest maximum diameter 
was the node containing métastasés, in four cases, smaller nodes 
were the sentinel nodes which contained tumour. There were two 
cases where more than one sentinei node per case contained 
tumour. In one of these two cases métastasés were found in the 
largest and second largest nodes and in the other case métastasés 
were found in the largest and smallest (the fourth largest) nodes.
The amount of radioactivity in the node was compared with the 
voiume of the node. Figure 27 shows the comparison of nodal 
volume and radioactivity content, and demonstrates almost no 
correlation (Pearson’s rank correlation coefficient (r) = 0.008). The
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correlation coefficient was similariy unimpressive for maximum nodai 
diameter and radioactivity content (r = 0.28)
The amount of radioactivity in a node was compared for positive and 
negative sentinel nodes. The mean radioactivity count for positive 
nodes was 980 counts/10 seconds and that for negative nodes was 
1554 counts/10 seconds. This difference was not significant (p = 
0.45).
The amount of radioactivity in the sentinel node was compared with 
the radioactivity count for the injection site at the tumour. Again, no 
correlation was found (r = 0.08).
When the tumour radioactivity was compared with the pathology of 
the node, no statistically significance in the mean tumour radioactivity 
was seen. The mean tumour radioactivity for negative nodes was 
18042 counts/10 seconds and that for positive nodes was 18900 
counts/10 seconds (p=0.8). This is demonstrated in Figure 28.
DISCUSSION
This part of the study was undertaken to determine whether tissue 
radioactivity levels and sentinel node size couid be used to predict 
sentinel node pathology. The most radioactive sentinei nodes within 
an individual case with large maximum diameters were more likely to 
contain tumour than smaller, less radioactive nodes within the case.
Nodes containing tumour had significantly larger maximum diameters 
than those nodes free from métastasés (18 mm versus 11 mm). This 
represented a difference of approximately 7mm, or 64% of the 
tumour free node.
The total volume of the lymph node was not significantly different 
between the two groups. This apparent paradox is probably due to 
the power of the study sample -  sixteen sentinel nodes were found to
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contain tumour, in comparison to 60 which were free from 
métastasés. The comparative difference in total volume of nodes was 
larger than that for maximum nodal diameter (789 mm^ versus 368 
mm^). This difference represents a difference of 421 mm^, or 114%, 
of the tumour free nodai volume however, the variability (standard 
deviation) of the volumes was much greater and accounts for the 
difference in significance. Thus, the paradox in significance may be 
expiained by the low power of the study.
The amount of radioactivity within a sentinel node was no guide to 
the size of the node or the probability that the node contained 
tumour. However, within a single patient the converse was true -  to 
accurately stage the neck, merely sampling the three hottest nodes 
or the two largest nodes were sufficient for diagnostic purposes. 
More than one hot node was found in 20 cases. When the amount of 
radioactivity within sentinel nodes was analysed in each patient with 
positive sentinel nodes, it was seen that the hottest nodes were more 
likely to contain tumour and the largest nodes were most likely to be 
metastatic. Thus, in the 16 tumour containing sentinei nodes, nine 
were the hottest nodes, four were the second hottest nodes and one 
was the third hottest node. The remaining two hot nodes were weakly 
radioactive, but were found in patients with more than one hot 
positive node. Also, 12 of the 16 positive nodes were the largest 
sentinel nodes and three of the 16 were the second largest nodes. In 
the one remaining case, the 4^  ^ largest node contained tumour in a 
case where a larger node also contained tumour.
We conciude that if a sentinel node biopsy procedure suggests 
harvesting many small nodes that are weakly radioactive, additional 
information might not be gained by harvesting more than the three 
hottest and the two largest lymph nodes. Clearly, with the low power 
of this study, this conclusion must be interpreted with caution.
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Limiting sentinel node biopsy to large and highly radioactive nodes 
might be necessary but only in the context of a complex neck 
exploration for sentinei nodes.
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TABLES AND FIGURES
Figure 23: Confirming radioactivity of nodes ex-vivo
(original in colour)
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Figure 24: The maximum diameters of lymph nodes
(original in colour)
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Figure 25: Box plot comparing the maximum diameter of 
positive and negative nodes, showing statistical significant 
differences
(original in colour)
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Figure 26: Comparison of maximum nodal diameters from 
nodes containing and free from tumour
(original in colour)
52 4  -
negativeU IJ positive
Pathology of node
3  5 7 9  11 13 15  17 19 22  25  30  40
Maximum dimension of node in mm
117
Figure 27: A comparison of nodal volume and amount of 
radioactivity, showing the best fit curve
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Figure 28: Comparison of tumour radioactivity by positive and 
negative sentinel nodes
(original in colour)
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Table 12: The rank (per patient) of radioactive nodes with their 
pathology
Hottest Node in Patient Pathology of node Total
negative Positive
Hottest node in patient 25 9 34
2 "  ^hottest node in pt 15 4 19
3"^  ^hottest node in pt 1 1 1 1 2
4**^  hottest node in pt 4 2 6
5*^  hottest node in pt 3 3
6 *^  hottest node in pt 2 2
Total 60 16 76
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Table 13: The rank of the maximum diameter of the sentinel 
node per case compared with the pathology of the node
Maximum diameter of 
node per patient
Pathology of node Total
negative positive
Largest node in patient 25 1 2 37
2 "  ^ largest node in pt 13 3 16
largest node in pt 13 0 13
4^  ^ largest node in pt 5 1 6
5^  ^ largest node in pt 2 2
6 *^  largest node in pt 2 2
Total 60 16 76
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CHAPTER 8: THE ANATOMICAL SITE OF SENTINEL 
LYMPH NODES IN THE NECK
INTRODUCTION
Lymphoscintigraphy and sentinel node biopsy have identified first 
echelon nodes at clinically unpredictable sites in breast cancer and 
melanoma. These nodes are first echelon nodes but represent the 
varied direct lymphatic drainage of tumours.
In cutaneous melanoma, the sentinel nodes are found at 
unpredictable sites in up to 25% of r e p o r t s F o r  
example, lymph node drainage of the skin of the back has been 
described to the intra-abdominal region^^®, drainage from the forearm 
has been seen to go directly to the supraclavicular nodes^ ®®, head 
and neck melanoma has been seen to bypass nodes in close 
proximity to the tumour to pass into nodes located at unusual sites^ '^ ,^ 
and finally, lymph nodes in the neck have received drainage from 
tumours located in the upper thorax^ "^ ®.
In breast cancer sentinel node biopsy, a similar, though less varied 
pattern has been seen. Lesions located laterally in the breast have 
drained directly to the intercostal nodes and first echelon nodes have 
been seen in the supraclavicular region, the infraclavicular region 
and even to the contralateral chain of Internal mammary or axillary 
nodes "^^ .^
In head and neck cancer, the nodes most likely to be involved in 
cancer are those located in levels l-lll^ "^ ®. Level IV nodes are involved 
in approximately 5% of clinically node negative necks and level V 
involvement in the clinically NO neck is exceedingly rare "^ ’^®^ ’^ "^®. Thus, 
a supraomohyoid neck dissection is often used for staging 
purposes^^°. Regional failure following a pathologically negative
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supraomohyoid neck dissection occurs in approximately 5% of 
cases, and these can be both within the operated field or out with the 
operated field®®. If the recurrence is out with the operated field, the 
node dissection failed to include the first echelon nodes for the 
tumour.
Although the patterns of lymph node métastasés for head and neck 
cancer are known from both retrospective studies and from cadaveric 
studies little is known on the dynamic drainage of lymph from the 
upper aerodigestive tract. For example, Figure 29 shows the 
drainage of the tongue to be to nodes situated in levels l-lll, and as 
such a neck dissection is used in many centres for staging tongue 
cancers.
This part of the study was performed to map the anatomical location 
of sentinel nodes from various anatomical sites to the neck to 
determine the pattern of lymph flow from primary site to sentinel 
nodes, in those cases where sentinel node pathology accurately 
reflected that of the remainder of the neck.
METHODS
Patients included in the study were those who had sentinel node 
biopsy performed using a combination of radiocolloid and blue dye. 
Only those cases where the sentinel node pathology was a true 
indicator of the neck pathology were included. Thus, all true positive 
and true negative sentinel node biopsies were included. Patients with 
pN+ necks were included in the study if the sentinel node also 
contained tumour. Excluded were those cases where the sentinel 
node did not reflect the neck pathology. This included patients with 
clinically NO (cNO) and clinically node positive (cN+) necks where the 
sentinel node was apparently free from tumour. Patients were 
excluded if they had undergone a sentinel node biopsy in the
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absence of a neck dissection since the sensitivity of the procedure is 
currently unknown and will only emerge with extended follow-up.
Patients were categorised by primary site. The tumour location was 
recorded as floor of mouth (FOM), tongue, retromolar trigone, soft 
palate, hard palate, buccal mucosa, tonsil and lip. The level within 
the neck site of the sentinel nodes was recorded to obtain the 
position of the sentinel nodes. Each neck explored for a sentinel 
node was considered a single case.
RESULTS
One hundred and twenty four sentinel nodes were harvested from 52 
necks. The distribution of primary tumours is shown in Table 14. 
Results were considered by tumour site.
T o n g u e  TUMOURS
Twenty-three necks were explored for sentinel nodes in patients with 
tongue malignancies. Four cases of ventral tongue tumours which 
encroached onto the anterior floor of mouth were included as tongue 
tumours. In all cases, the sentinel node pathology reflected that of 
the neck. Twenty-one cases were squamous cell carcinomas and 
two were melanomas. Sixty-five nodes were found in total. Six 
sentinel nodes were found in level I, 34 were found in level II, 21 
were found in level III and four in level IV. Lymphoscintigraphy 
identified one “hot spot” within the tonsils from a mid-lateral oral 
tongue tumour (Figure 30); a tonsillectomy was not performed to 
harvest a sentinel node in the patient, who was subsequently staged 
as pNO.
Three sentinel nodes from well lateralised tongue cancers were 
found in the contralateral neck and one sentinel node in level II was 
found in level lib. Two of the level IV nodes contained tumour but the
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nodes in level lib and in the contralateral neck did not contain 
métastasés. Figure 31 summarises the percentages of the locations 
of sentinel nodes.
F l o o r  o f  m o u t h  T u m o u r s
Fourteen necks were explored for sentinel nodes in patients with 
FOM cancers. In all cases, the sentinel node pathology reflected that 
of the neck. Twenty-eight nodes were found in total. Five nodes were 
found in level I, 15 nodes were found in level II and eight nodes were 
found in level III. Figure 32 shows the percentage distribution of 
sentinel node locations from cancers of the FOM.
R e t r o m o l a r  t r ig o n e  t u m o u r s
Five necks were explored for sentinel nodes in patients with RMT 
cancers. In all cases, the sentinel node pathology reflected that of the 
neck. Thirteen nodes were found in total. Two nodes were found in 
level I and 11 nodes were found in level II, this included one node in 
level lib. The node from level lib did not contain métastasés. Figure 
33 shows the percentage distribution of sentinel node locations from 
cancers of the RMT.
S o f t  p a l a t e  t u m o u r s
Four necks were explored for sentinel nodes in patients with soft 
palate cancers. In all cases, the sentinel node pathology reflected 
that of the neck. Seven nodes were found in total. One node was 
found in level I, three nodes were found in level II, two nodes were 
found in level III, no nodes were found in level IV and one node was 
found in level V. The node in level V did not contain métastasés. 
One “hot spot” on lymphoscintigraphy was found to be an area within 
the tonsils (Figure 34). The tonsils were not explored in this case, 
and no sentinel node from the tonsil was harvested.
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Figure 35 shows the percentage distribution of sentinel node 
locations from cancers of the soft palate.
B u c c a l  m u c o s a  t u m o u r s
Two necks were explored for sentinel nodes in patients with buccal 
mucosa cancers. In both cases, the sentinel node pathology reflected 
that of the neck. Five nodes were found in total. Two nodes were 
found in level I, one node was found in level II and two nodes were 
found in level III.
H a r d  p a l a t e  t u m o u r s
Two necks were explored for sentinel nodes in two patients with hard 
palate cancers. One case was a squamous cell carcinoma and one 
was a malignant melanoma. Two nodes were found, both in level I 
but in one case the node was found in the contralateral side of the 
neck to the tumour. The node found on the contralateral side of the 
neck was found in a patient with oral melanoma and contained 
melanin pigmentation within macrophages.
T o n s il l a r  t u m o u r s
Two necks were explored for sentinel nodes in patients with tonsillar 
tumours. Three sentinel nodes were found in level II.
U p t u m o u r s
In one case of a lip tumour, the sentinel node was found in level II. 
DISCUSSION
This part of the study was performed to map the spread of colloid 
and blue dye from primary site to sentinel node in the 52 cases of 
true positive or true negative sentinel node biopsy. Although there 
were some unexpected sites of first echelon nodes most sentinel 
nodes were found as clinically expected in levels l-lll. Of the 124
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sentinel nodes that were harvested, 113 (91%) were found in the 
ipsilateral levels Mil.
Sentinel nodes were found in level lib. Although level lib is part of a 
neck dissection in which level II is removed, there has been recent 
debate over the need for exploration of this, the most technically 
challenging part of dissecting level ll^^\ Since sentinel nodes were 
found in this regions, if a neck dissection is to be performed to 
accurately stage the neck, then all sentinel node regions should be 
dissected. The nodes in level lib did not, however, contain 
métastasés.
Sentinel nodes were found at unexpected sites. Nodes were located 
in level IV, level V, in the contralateral neck from well lateralised 
tumours and in the tonsils, though in the latter case tonsillectomies 
were not performed. Four nodes were located in level IV, one node 
was found in level V, four nodes were found in the contralateral neck 
and two nodes were identified during lymphoscintigraphy in the 
tonsils. One contralateral node was found to contain evidence of 
possible early tumour spread and two of the sentinel nodes in level 
IV were found to contain tumour. Thus, in total there were 11 nodes 
(including the tonsillar sentinel nodes) found at unpredictable sites. 
With the addition of two tonsillar sentinel nodes, the total number of 
nodes would have been 126 and so 9% of nodes were at unusual 
sites. It is unusual to see tonsillar métastasés from tumours located 
in the oral cavity and level V nodal involvement is exceedingly rare in 
the cNO neck "^ ’^^^ ’^ ^^ .
Sentinel node biopsy is redefining lymphatic flow from our traditional 
belief. There is considerable variability of lymphatic drainage 
between individuals, even from those sites where it was thought to 
be highly predictable. This study has confirmed that the variability in 
lymphatic drainage seen in sentinel node biopsy of breast cancer and
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cutaneous melanoma is also seen in oral and oropharyngeal cancer 
sentinel node biopsy.
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TABLES AND FIGURES
Figure 29: Cadaveric studies demonstrating tongue lymphatic 
drainage (from Human Anatomy, Churchill Livingstone, 3rd 
Edition, 1982)
(original in colour)
M
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Figure 30: Lymphoscintigraphy image of sentinel nodes from a 
lateral tongue tumour -  the highest hot spot was found to be 
located in the tonsillar region at operation
(original in colour)
□
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Figure 31: Tongue cancer sentinel node distribution
(original in colour)
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Figure 32: FOM cancer sentinel node distribution
(original in colour)
54% 18%
29%
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Figure 33: RMT cancer sentinel node distribution
(original in colour)
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Figure 34: Lymphoscintigraphy highlighting two sentinel nodes 
in the neck and one sentinel node in the tonsillar region
(original in colour)
i
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Figure 35: Soft palate cancer sentinel node distribution
(original in colour)
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Table 14: Distribution of tumour and nodes where sentinel node 
pathology reflected that of the remaining neck nodes
T u m o u r  SITE N u m b e r  of 
CASES
N u m b e r  of
SENTINEL NODES
M ean  n u m b e r
OF NODES PER 
CASE
Tongue 23 65 2 . 8
FOM 14 28 2
RMT 5 13 2 .6
Soft palate 4 7 1.75
Buccal mucosa 2 5 2 .2
Hard Palate 2 2 1
Tonsil 2 3 1.3
Lip 1 1 1
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CHAPTER 9: SENTINEL NODE BIOPSY TO TARGET 
NECK DISSECTION AT THE CLINICALLY FALSE 
NEGATIVE NECK
INTRODUCTION
Sentinel node biopsy has become the standard of care in cutaneous 
melanoma in the USA, although in breast cancer it has not yet 
replaced axillary node sampling^^ '^^^®. In the USA, it was common 
practice to perform elective neck dissections on patients with 
melanomas, since one randomised controlled trial had shown 
elective lymph node dissection to be of possible benefit in a 
subgroup of patients^®^.
Sentinel node biopsy has now replaced elective node dissection as 
the standard of care in cutaneous meianoma^^®. The pathological 
status of the sentinel node is the most accurate prognostic indicator 
of recurrence and patients with a sentinel node free of tumour
are unlikely to develop further regional recurrence^®\ This is reflected 
in the new American Joint Committee on Cancer (AJCC) staging 
system that has been proposed for melanoma which will be used 
from 2002^® .^ In the new system, patients with subclinical nodal 
métastasés will be upstaged. Subclinical disease may be determined 
with a sentinel node biopsy in the new AJCC TNM classification.
The concern that a surgical procedure to excise a lymph node 
containing tumour within the regional lymph node basin will 
compromise the oncological management of the patient has been 
addressed recently^® .^ The results of this study suggest that 
subsequent regional failure following a positive sentinel node biopsy 
and lymph node dissection is a function of tumour aggression rather 
than surgical interruption of metastatic lymphatics, although this
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study was performed in melanoma patients and the results may not 
necessarily be transferable to oral SCC patients. Additionally, the 
follow up in this paper is somewhat limited.
Thus it can be seen that sentinel node biopsy has been successfully 
applied to other cancers, particularly cutaneous malignant 
melanoma, and the procedure can accurately stage the regional 
lymph node basin without compromising the oncological safety of 
patient management. This section of the study was performed to 
determine whether the sentinel node could be identified in head and 
neck cancer patients, out with the context of a neck dissection. The 
aims were to harvest the sentinel node and examine the node for 
pathological evidence of tumour. The sensitivity of the procedure was 
not one of the aims of the study, since this would require long term 
follow-up, and forms the basis of another study.
METHODS
Patients were entered into our study following ethical approval from 
the local ethics committee and informed consent. Up to 24 hours 
prior to surgery, patients were injected with up to 40MBq of colloidal 
human serum albumin (HSA) in a volume of up to 1ml to completely 
surround the tumour on the lateral and deep aspects. The colloid 
used varied with anatomical site of primary. Albures (Nycomed 
Amersham, High Wycombe, Bucks, UK) was used for primaries of 
the tongue and floor of mouth. Nanocoll (Nycomed Amersham, High 
Wycombe, Bucks, UK) was used for primaries of other anatomical 
sites. Following injection of colloid, patients were given a mouthwash 
to prevent pooling and swallowing of radioactivity. Static 
lymphoscintigraphy was performed using a gamma camera fitted with 
a low energy, general purpose collimator and a 2 0 % window was 
selected at the 140keV photopeak. Lymphoscintigraphy was
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performed at 15 minute intervals up to one hour following injection, or 
until the first appearance of radioactivity within the neck. The site of 
the radioactive nodes were marked on the skin of the neck and 
images were acquired.
During surgery, Patent Blue V dye (Laboratoire Guerbet, Aulnay- 
Sous-Bois, France) was injected at the same sites as radiocolloid, in 
a volume of up to 2ml. A neck incision was made from the anterior 
border of the sternomastoid muscle to the lateral border of the strap 
muscles of the neck and subplatysmal flaps were raised to explore 
the neck. The hand held gamma probe was used to identify 
radioactive nodes and blue lymphatics were traced to blue lymph 
nodes. All sentinel nodes were identified in their anatomical groups. 
All blue and radioactive nodes were harvested as sentinel nodes and 
the presence of radioactivity within sentinel nodes was confirmed ex- 
vivo. The surgical procedure was completed by suitable treatment of 
the primary and the insertion of a small drain into the neck. No nerve 
damage occurred to the spinai accessory nerve in this series of 
patients.
Frozen section analysis of the sentinel node was used in one case 
only. In the remaining cases, following fixation, lymph nodes were 
bisected through their hilum, if identifiable, or long axis. Both sections 
from each half was processed for evidence of tumour on H&E 
staining. If nodal métastasés were identified, the patient was 
informed and was advised to undergo a modified radical neck 
dissection. The neck dissection was therapeutic and permitted formal 
pathological staging of neck disease. If the sentinel node was free of 
tumour, no further treatment to the neck was performed. Patients 
were followed for 6-14 months following their procedure.
No patient required access to the neck and mandibulotomy for 
access to the tumour, as is occasionally required in retromolar
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trigone tumour ablation. A laser was not used for surgical excision, 
and all patients underwent scalpel tumour excision. One patient 
underwent free flap reconstruction to the resulting defect of a floor of 
mouth tumour. All remaining patients underwent either direct closure, 
local flap or skin grafting to the ablative defect.
RESULTS
Sixteen patients were investigated. The male: female ratio was 3:1 
and the mean age was 58 years (range 33-88). Sentinel nodes were 
found in 15 of 16 patients. One patient with a T2 midline SCC of the 
dorsum of tongue had lymph drainage to both necks and so 16 neck 
sides were explored for sentinel nodes. Eleven patients were 
classified as T1, three as T2 and 2 as T4. The size of the T4 tumours 
was not measured by CT scanning, but determined clinically at 
examination under anaesthesia by an experienced consultant.
Carcinoma of the tongue comprised seven cases, seven cases were 
carcinomas of the floor of mouth, one was a T2 SCC of the 
retromolar trigone and one case was a T4 SCC of the upper 
alveolus.
The total number of sentinel nodes harvested was 34 (mean per 
patient 2.1) Eleven nodes were hot, 2 nodes were blue and 21 nodes 
were hot and blue. The figure below shows the number of sentinel 
nodes harvested from each patient and the figure below shows the 
neck levels from which sentinel nodes were harvested.
Two sentinel nodes contained tumour from two patients and a 
modified radical neck dissection was subsequently performed in each 
case, in the first case, the sentinel node was a hot blue node from 
level III in a patient with a T1 floor of mouth tumour. A modified 
radical neck dissection was subsequently and a further two nodes
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(from levels I and II) were found to contain tumour. In the second 
case, the sentinel node containing tumour was a hot blue node from 
level I in a patient with a clinicaliy T1 lateral tongue tumour, which 
was pathoiogically classified as T4. A subsequent neck dissection 
was performed an no other nodes contained tumour. Frozen section 
pathological examination of the sentinel node was used in one 
patient, in whom a decision was made to minimise the number of 
potential surgical procedures. Sentinel node pathology was negative 
and no neck dissection was performed.
No patient has subsequently developed nodal disease within the very 
short follow-up time. No patient with a sentinel node free of tumour 
métastasés has undergone any elective treatment to the neck in the 
form of surgery or radiotherapy and long term follow-up is being 
performed on ail patients entered into our on-going study.
DISCUSSION
This study was performed to determine if the sentinel node could be 
identified in patients undergoing no elective treatment to the neck. 
When using a combination of blue dye and radiocolloid injection, our 
success rate in identifying sentinel nodes within the neck is 15/16 
(94%). This compares favourably with the rate of sentinel node 
identification in patients undergoing sentinel node biopsy for 
cutaneous lesions of the head and
The procedure in head and neck cancer may be more technically 
demanding than in head and neck melanoma. Oral SCC lesions are 
usually ulcerated and are close to the primary site. Ulceration allows 
leakage of radiocolloid from the injection site into the mouth, where 
radioactivity may be pooied in the floor of mouth, or swallowed. In 
either situation, lymphoscintigraphy will identify areas of radiocolloid 
out with sentinel nodes. The close proximity of sentinel nodes to the
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primary site, especially when the primary site is the floor of mouth, 
renders gamma probe identification of radioactive nodes in the 
submandibular and submental triangles difficult. By using a series of 
malleable lead plates to shield the injection site, shine through and 
scatter from the primary site is reduced and radiolocalisation is aided. 
The use of blue dye for level I exploration also aids in the 
identification of sentinel nodes.
Human serum albumin (HSA) is available in two preparations, 
Albures and Nanocoll. Albures has a mean particle size of 500nm 
and that of Nanocoll is 80nm. The former passes from injection site 
to lymph nodes slowly and requires a high density of terminal 
lymphatics within the tissues to enter the sentinel node but remains 
within the first echelon node, whereas Nanocoll passes easily from 
injection site to lymphatic vessels but also passes from the first 
echelon lymph node to non-sentinel nodes. The choice of colloid was 
determined by the site of primary disease. Lesions of the tongue and 
floor of mouth were injected with Albures and primaries at other sites 
were injected with Nanocoll. There is no consensus of opinion as to 
which is better for sentinel node localisation in head and neck SCC, 
however our experience suggests that the choice of colloid can be 
determined with the site of the primary, particularly in view of the 
density of terminal lymphatics within the differing oral tissues. Future 
studies should explore the use of different colloids as part of a 
randomised controlled trial.
Using these colloids with pre-operative lymphoscintigraphy and per- 
operative use of the hand held gamma probe in addition to blue dye 
visualisation, sentinel node biopsy may ultimately become an 
alternative to a “wait-and-see” approach to the clinically NO neck. 
Clearly, however, sentinel node biopsy will require further studies
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before it becomes the standard of care in patients with early cancers 
of the oral cavity rather than elective “staging” neck dissection.
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TABLES AND FIGURES
Figure 36: Number of sentinel nodes per patient in those 
undergoing sentinel node biopsy only
(original in colour)
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Figure 37: Sentinel node locations in patients undergoing 
sentinel node biopsy only
(original in colour)
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CHAPTER 10: OVERALL RESULTS 
INTRODUCTION
In this study, sentinel node biopsies have been performed on 
patients with mucosal head and neck cancers. Each neck side 
explored for sentinel node biopsy has been considered a single case, 
since one of the main aims of the project was to determine whether 
the sentinel node could correctly identify the presence of tumour in 
the neck of patients with head and neck cancer.
Sentinel node biopsy using blue dye alone was performed in 16 
cases (in 16 patients), sentinei node biopsy using a combination of 
blue dye and radiocolloid was performed in 40 clinically NO necks 
(from 37 patients) and 27 clinically N+ necks (from 25 patients) in 
patients where neck dissections were also performed. Additionally, 
17 necks were explored in 16 patients for sentinel nodes who did not 
initially undergo a neck dissection and three necks were explored for 
sentinel nodes in two patients with oral melanoma. In total, 103 
necks were explored for sentinel nodes in 96 patients.
BLUE DYE SENTINEL NODE BIOPSY
Sentinel node biopsy using blue dye alone was performed in 16 
cases. Eight of these were in the clinically NO neck and eight were in 
the clinically N+ neck.
In the clinically NO group, four patients were pNO and four were pN+. 
In the pN+ group, a blue node was found in two cases but these blue 
nodes did not contain tumour. In the pNO group, a sentinel node was 
found in all four cases and the sentinel node was free from apparent 
métastasés, by definition.
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In the clinically N+ group, seven cases were pN-s- and one case was 
pNO. in the pN+ group, a blue node was found in one case but did 
not contain tumour. In the one pNO case, no sentinel node was 
found.
Thus, sentinel nodes were found in seven cases of 16 and none of 
these contained tumour by routine pathology. In these seven cases, 
tumour was present in the neck in three cases, and in each case a 
sentinel node did not contain tumour. In conclusion, sentinel node 
biopsy using blue dye alone was not successful as a staging 
procedure.
SENTINEL NODE BIOPSY WITH BLUE DYE AND 
RADIOCOLLOID
Sentinel node biopsy using radiocolloid in addition to blue dye 
injection was performed in 8 6  of the remaining 87 cases. In one 
patient with oral melanoma, the sentinel node was harvested using 
only radiocolloid, since it was felt that injection of blue dye into the 
mucosa would potentially compromise the oncological safety of the 
excision of the primary tumour, by blurring its margins.
CHOICE OF COLLOID IN HEAD AND NECK CANCER SENTINEL 
NODE BIOPSY
Sixty-seven necks were explored for sentinel nodes, in 62 patients 
undergoing a neck dissection for squamous cell carcinoma of the oral 
cavity or oropharynx. Each neck side was considered a single case. 
In patients with floor of mouth cancer 18 necks were explored and 
the colloid used was Albures in all cases. A radioactive node was 
found in 14 of these 18 (78%). In patients with tongue cancer, 26
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necks were explored and the colloid used was Albures in all cases. A 
radioactive node was found in 21 of the 25 necks (84%).
In patients with tumours of other sites within the head and neck, 
Albures was used in eight cases and Nanocoll was used in 15. When 
Albures was used a hot node was found in three of eight cases 
(38%) and when Nanocoll was used a hot node was found in 13 of 
15 (87%). This difference was statistically significant using the Mann- 
Whitney U test (p=0.15).
THE CLINICALLY NO NECK
Using a combination of blue dye and radiocolloid injection, 40 cases 
of sentinel node biopsy were performed on 37 patients with cervical 
nodes clinically clear of métastasés. One case was staged clinically 
as Nx in a patient with long standing cervical lymphoma and was 
included in the results of the clinically NO group. Sentinel nodes were 
found in 35 of these 40 cases (8 8 %). Twenty cases were 
pathologicaiiy NO and 20 were pN-r. in the 20 pNO cases, sentinel 
nodes were found in 19 cases (95%) and, by definition, the sentinel 
node was free from apparent tumour. The remaining 20 cases were 
staged pN-r with routine histology. In these cases, a sentinel node 
was found in 17 cases (85%) and contained tumour in 16 (94%). In 
1 2  of these 16, the sentinel node was the only node containing 
tumour. In these 16 cases, 18 sentinel nodes contained tumour, of 
which the node was hot and blue in 1 0 , hot only in six and blue only 
in two. In three of four cases where sentinel nodes were not identified 
in the neck, the neck nodes contained tumour.
THE CLINICALLY INVOLVED NECK
Sentinel node biopsy was performed in 25 patients undergoing 27 
therapeutic neck dissections. In 18 cases (17 patients), sentinel node
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biopsy was performed using the large diameter radiocolloid Albures 
and in 9 cases ( 8  patients), sentinel node biopsy was performed 
using the smaller diameter radiocolloid Nanocoll. In the 17 cases in 
which Albures was used, a sentinel node was found in 15. Of these 
15, tumour was found in the neck in 1 2  and the “sentinel” node 
contained tumour in two of these 12 (14%). In the nine cases in 
which Nanocoll was used, a sentinel node was found in eight. The 
neck contained métastasés in seven of these eight cases and the 
sentinel node was involved with overt métastasés in six cases (8 6 %). 
In conclusion, sentinel node biopsy using Albures was unsuccessful 
in the clinically N+ group, but when using Nanocoll, the procedure 
was more promising.
SENTINEL NODE BIOPSY IN ORAL MELANOMA
Sentinel node biopsy was performed in two patients with oral 
melanoma. One patient was suffering from a melanoma of the 
tongue and the other a melanoma of the hard palate mucosa. 
Sentinel nodes were found in both cases. Albures and blue dye was 
used for sentinel node biopsy in the tongue melanoma whereas 
Nanocoll was used to harvest the sentinel node in the palatal 
melanoma.
In the patient with a tongue melanoma, sentinel nodes were found in 
both sides of the neck despite the tumour being well lateralised. Six 
sentinel nodes were found, and none contained métastasés. Three of 
the sentinel nodes were found in the ipsilateral neck and three in the 
contralateral neck but none contained tumour métastasés.
In the patient with a palatal melanoma, the tumour was located to the 
left of the midline, and one sentinel node was found in the right 
submandibular region. Although the sentinel node did not contain
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viable tumour, macrophages within the node were stained with 
melanin.
SENTINEL NODE SIZE AND RADIOACTIVITY
In patients undergoing a neck dissection, 34 necks were identified in 
which at least one radioactive node was present. Within these 34 
necks, 76 sentinel nodes were radioactive. Tumour was present 
within 16 nodes and 60 nodes were free from tumour. In 14 cases a 
single hot node was found, two hot nodes were found in eight cases, 
three hot nodes were found in six necks, four hot nodes were found 
in three necks, five hot nodes were found in one neck and six hot 
nodes were found in two necks.
Lymph nodes containing tumour had a greater maximum diameter 
than those free from tumour. The mean maximum diameter of 
positive nodes was 18 mm and that for negative nodes was 1 1  mm.
Although there was no correlation between the amount of 
radioactivity in the node and likelihood of that node containing 
tumour, the hottest and largest nodes within each patient were the 
most likely to contain métastasés. The three hottest sentinel nodes in 
each patient gave enough staging information for the neck of each 
patient to be accurately staged, as did the two largest sentinel nodes 
within the neck.
THE ANATOMICAL SITE OF SENTINEL NODES IN THE NECK
There were 124 sentinel nodes harvested from 52 necks in which the 
sentinel node pathology reflected that of the neck. Twenty three 
cases were of tongue tumours and 65 sentinel nodes were obtained 
from this group. Fourteen cases were of floor of mouth tumours and 
28 sentinel nodes were obtained from this group. Five cases were of
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retromolar trigone tumours and 13 nodes were obtained from this 
group. Four cases were of soft palate tumours and seven nodes 
were obtained from this group. The remaining cases were from 
tumours of the buccal mucosa (two cases, five nodes), hard palate 
(two cases, two nodes), tonsil (two cases, three nodes) and lip (one 
case, one node).
The sentinel nodes from tongue tumours were found mainly in levels 
I (six nodes), II (34 nodes) and III (21) within the neck. Sentinel 
nodes were also found in level IV (four nodes) within the tonsil (one 
node identified at lymphoscintigraphy but not excised), in the 
contralateral neck and in level MB.
The sentinel nodes from floor of mouth tumours were found in levels I 
(five nodes), II (15 nodes) and III (eight nodes). No unusual sites of 
sentinel nodes were found in floor of mouth cancers.
The sentinel nodes from retromolar trigone tumours were found in 
levels I (two nodes) and II (eleven nodes). One node was found 
within level MB.
The sentinel nodes from soft palate tumours were found in levels I 
(one node), II (three nodes). Ml (two nodes) and level V (one node). 
One node was also found in the tonsils during lymphoscintigraphy, 
but was not excised.
Sentinel nodes from tumours of the buccal mucosa, hard palate, 
tonsils and lip were found in levels I, II and Ml only.
SENTINEL NODE BIOPSY TO UPSTAGE THE CLINICALLY NO 
NECK
In 16 patients, 17 necks were explored for sentinel nodes. Sentinel 
node biopsy was performed using a combination of blue dye and
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radiocolloid injection. In this setting, it was thought more appropriate 
to consider each patient as a single case, rather than each neck. 
Sentinel nodes was found in 15 of 16 patients (94%) and a tumour 
containing sentinel node was present in two patients. And these two 
patients underwent therapeutic neck dissections. Since follow up for 
this group of patients was short, the overall sensitivity of the 
procedure is not yet known.
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CHAPTER 11: OVERALL DISCUSSION
In the studies enclosed within this Thesis, the sentinel node concept 
has been investigated in patients with head and neck cancer. The 
technique was initially applied with a view to formulate a method with 
which to identify the sentinel node. The technique with blue dye was 
discarded in favour of sentinel node biopsy using a combination of 
lymphoscintigraphy, blue dye and the hand held gamma probe. 
Subsequently, the Nuclear Medicine and Surgical techniques were 
refined to enable the harvesting of the sentinel node from the neck. 
Finally, the technique was applied to a group of patients in whom the 
clinical decision would have been to observe their neck. In this group, 
a neck dissection was only performed if the sentinel node was found 
to harbour subclinical métastasés. The protocol for a multicentre trial 
was then written to formally evaluate and validate the accuracy and 
reproducibility of the procedure.
The sentinel node concept has recently become accepted as a 
means of identifying the presence of nodal métastasés in a variety of 
cancers "^^®. The idea that lymph node métastasés are embolic in 
nature and that nodal spread is both orderly and progressive has 
been shown to be valid in the context of many carcinomas that 
spread initially via the lymphatic system^®®.
The cancers most investigated are breast cancer^®  ^ and cutaneous 
melanoma^®® where there is little debate over the accuracy of the 
technique. In both malignancies, the sentinel node accurately stages 
the regional lymph node basin in over 90% of cases 
Additionally, in melanoma, the pathological status of the sentinel 
node is the most accurate prognostic indicator for regional 
recurrence. The chance of recurrence in patients with a sentinel node 
free of tumour, is approximately 1 G%^®\ whereas that for patients
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with a sentinel node containing tumour, despite the tumour thickness, 
is approximately 35%^ ®®-^ °^. This prognostic accuracy is reflected in 
the new proposed American Joint Committee on Cancer staging 
classification for melanoma, which will be used from 2 0 0 2 ®^®, in 
which a patient with sentinel node métastasés is upstaged. Whether 
knowledge of the status of the sentinel node pathology makes a 
difference to patient outcome is unknown but unlikely^^\ However, 
this is being investigated in a large multicentre international study, 
co-ordinated at the John Wayne Cancer Institute in Santa Monica, 
California^^^. This is a trial of primary excision alone versus wide 
excision and sentinel node biopsy. If the sentinel node is found to 
contain tumour in the group of patients that undergo a sentinel node 
biopsy, the patient undergoes a therapeutic lymph node dissection, 
and a therapeutic dissection is only performed in the group 
undergoing wide excision alone if subsequent clinical examination 
reveals lymphadenopathy. The end points of the trial are survival to 
five years, regional recurrence and death; the results of the trial will 
become available within a few years. Further trials are now emerging 
with patient stratification into various therapeutic arms depending on 
the status of the sentinel node^^®. If the sentinel node is merely an 
indicator of widespread disease, then patients with known 
métastasés can be entered into trials of systemic therapy if the 
sentinel node contains tumour. Also, since approximately 75% of 
patients with nodal micrometastases in the sentinel node are free of 
métastasés in the remaining lymph node basin®^ "^ , further trials are 
underway to determine if a complete lymph node dissection is 
necessary following a positive sentinel node biopsy®^ ®, especially in 
patients with thin primaries, where the rate of non sentinel 
métastasés in the presence of a pathologically involved sentinel node 
is even lower®^ ®. Again, the results of these trials will emerge with 
time.
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Several controversies still exist surrounding the methodology of 
sentinel node biopsy in melanoma®^^ and breast cancer 
patients®®^ '®^ ®. In the nuclear medicine part of the procedure, 
unanswered questions include whether the patient should undergo 
dynamic as well as static lymphoscintigraphy, which colloid should be 
used, how often should scintillation images be taken and where 
should the injection be given (i.e. into the tumour, to surround the 
tumour or into the skin overlying the tumour in the case of breast 
cancer), the quantity of radiocolloid (in ml) and the amount of 
radioactivity in the colloid (in MBq) are also a matter for debate. 
Similarly, the controversies in the surgical technique include the 
amount of blue dye to use, whether the procedure can be performed 
with blue dye or radiocolloid only, which gamma probe should be 
used, whether all blue and radioactive nodes need to be excised or 
whether the hottest or first nodes encountered should only be 
removed. Controversial aspects of pathology include whether the 
sentinel nodes should be examined with multiple serial sections and 
with immunohistochemistry. If immunochemical stains are to be 
used, which stains should be used and on what levels remains 
unanswered, as does the role of molecular analysis of the sentinel 
node using reverse transcriptase polymerase chain reactions looking 
for messenger RNA to tyrosinase®^ ®'®®® (in the case of melanoma) or 
a keratin protein®^®’®®"^ '®®® (in the case of breast cancer). Lastly, if the 
sentinel node is found to contain tumour, it is unknown whether to 
remove the remaining non sentinel nodes from the lymph node basin, 
especially for early primary disease.
The most controversial area surrounding sentinel node biopsy is in its 
ability to alter survival for patients®^ '^®®^ . In the USA, where elective 
lymph node dissection was often performed for cutaneous 
melanoma®®®, the idea of performing a sentinel node biopsy instead
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of an elective node dissection was more acceptable than in Europe, 
where lymph node dissections were only performed for melanoma 
patients with palpable lymphadenopathy. However, since no 
randomised controlled trial in melanoma has shown that elective 
lymph node dissection can consistently and reliably alter patient 
survival, sentinel node biopsy remains controversial as a therapeutic 
procedure. If the presence of melanoma within the lymph nodes is 
merely an indicator of distant disease then early treatment of regional 
disease will make no difference to overall survival, although there 
may be a reduction in disease free survival. In head and neck 
cancer, however, patient mortality is most often due to local or 
regional failure and less so from distant métastasés®®’®®®. 
Management of head and neck cancer patients should initially be 
directed at adequate control of local and regional disease. If regional 
disease can be more effectively controlled by the treatment of early 
lymph node disease, then sentinel node biopsy may lead to a 
survival benefit for head and neck cancer patients. Since some 
patients with subclinical métastasés undergo observation of the 
lymph node group and develop late stage regional disease®®®'®®^  it is 
highly possible that sentinel node biopsy may confer a survival 
benefit. When locoregional control in head and neck cancer 
improves, the presence of distant métastasés becomes more 
relevant in determining survival.
In head and neck cancer sentinel node biopsy, all the above 
questions remain unanswered. Since the sentinel node concept has 
only recently been applied to this group of patients, the controversies 
are likely to remain for several years.
In our experience, we have found that the sentinel node is identifiable 
in patients with head and neck cancer, and that the sentinel node 
accurately reflects the pathological status of the neck, when
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successfully harvested. We have also applied the new technology to 
patients with early cancers who would otherwise undergo no elective 
treatment to the neck, and have found that the technique can 
upstage the neck in some patients. Although the exact sensitivity of 
the procedure is unknown, in the context of an elective neck 
dissection, the overall accuracy of the pathological status of the node 
is high.
During the sentinel node biopsy procedure, when the radiocolloid is 
used according to the anatomical site of the lesion, 
lymphoscintigraphy and the hand held probe will identify the position 
of the sentinel node in approximately 90% of cases. This rate 
compares favourably with cutaneous head and neck melanoma 
sentinel node biopsy, where the rate is between 90- 
100%®®'^ ®®’^^ ®’®®'^ ’®®®. For primary cancers located in the tongue or 
floor of mouth, the colloid we chose to use was Albures and for 
primaries located elsewhere in the oral cavity or oropharynx, the 
colloid was Nanocoll. If Albures is used in non-floor of mouth and 
non-tongue lesions, the colloid does not pass from injection site to 
the lymph nodes in the neck; conversely, if Nanocoll is used for 
lesions of the floor of mouth or tongue, the colloid would theoretically 
pass from first echelon node to non sentinel nodes, and a large 
number of radioactive nodes would be found in the neck. Although at 
least one of these nodes would be the sentinel node, unnecessary 
exploration of the neck would be performed in order to retrieve the 
true sentinel nodes. If Albures is used to investigate lymphatic flow in 
the clinically involved neck, the colloid bypasses grossly involved 
nodes to enter un involved, and therefore non-sentinel, nodes. The 
increased hydrostatic pressure within the grossly involved lymph 
node appears to be too high to permit the in flow of large diameter 
colloids. When using low diameter colloids, the sentinel node
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involved with tumour seems to take up the radiocolloid more often. In 
these cases, the increase in hydrostatic pressure within the involved 
node is not so high as to prevent the small colloid from passing into 
the node.
In those cases where a radioactive node is not found in the neck, the 
additional use of blue dye will aid in localising the sentinel node. 
Some blue nodes will contain métastasés yet will have no clinically 
detectable amounts of radioactivity within them, therefore blue dye 
should be used in addition to radiocolloid to identify the sentinel 
node. Since blue dye and radiocolloid are different pharmaceuticals, 
they will have different pharmacokinetics and pharmacodynamics. 
Accordingly, it is not surprising that some sentinel nodes are blue 
only or hot only. Sentinel nodes can be found in clinically 
unpredictable sites, or those sites within the neck that are technically 
challenging to approach (for example level Mb). Thus, the use of 
lymphoscintigraphy pre-operatively is a prerequisite to successful 
sentinel node identification and gives an indication to where to 
search for the sentinel nodes. Lymphoscintigraphy does not appear 
to be sensitive enough to locate the exact site of the sentinel node In 
terms of neck level. In our initial study using blue dye alone, one of 
the main problems in retrieving sentinel nodes was the lack of 
knowledge of where to search for blue dye. Although the neck is 
conveniently divided into levels according to the likely site of nodal 
metastasis, and although patients with oral and oropharyngeal 
cancers are likely to harbour métastasés initially in levels I, II or Ml, 
exploring the neck for blue dye is technically difficult if there is doubt 
as to whether the sentinel node will be present in the level being 
explored. There is also a learning curve associated with all sentinel 
node techniques®®’ ®^®, and this may have been reflected in our later 
success with successful identification of blue nodes in the absence of
158
radioactivity within the neck. As our experience with the procedure 
increased the success rate in identification rose, particularly when 
the exploration of the sentinel node was guided to the upper, middle 
or lower neck by lymphoscintigraphy.
Our experience suggests that the sentinel node pathology accurately 
reflects the status of the neck in the clinically NO neck, when the 
sentinel node is found. Lymph node métastasés are thought to be 
embolic in nature and these are thought to travel within lymphatics to 
the first echelon lymph node draining the tumour. The sentinel node 
concept of injecting traceable compounds into the metastasising 
edge of a tumour, and following these compounds to the first echelon 
node which is then removed and examined for the presence of 
tumour, seems to apply to head and neck cancer to the same degree 
that it does for breast cancer and melanoma. In our series, the 
accuracy of the procedure was 94%, (95% confidence interval 82- 
1 0 0 %, when a sentinel node was successfully identified), when 
performed in the context of an elective lymph node dissection. Since 
the presence of nodal disease in a sentinel node upstages the neck, 
by definition the specificity of the procedure is 1 0 0 % -  there can be 
no false positive sentinel node pathology results when using 
conventional H&E techniques. The overall accuracy of the procedure, 
in the context of an elective neck dissection, is therefore very high, 
when technically successful. If a sentinel node Is not found, there 
remains a high possibility that lymph node disease is present in the 
neck and clinicians should strongly consider performing an elective 
neck dissection in such cases.
In melanoma and breast cancer, sentinel node pathology is the most 
accurate way of staging the regional nodes and in our experience 
with head and neck cancer sentinel node biopsy, it seems that the 
sentinel node status is also the most accurate means of staging the
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neck. The accuracy in our series was higher than that for clinical 
examination or radiological investigative techniques®®®, other than the 
results from the Amsterdam group where ultrasound guided fine 
needle aspiration is performed with greater sensitivity. However, the 
Dutch group’s experience is not reflected in any other head and neck 
unit. This being the case, it is a logical progression that the technique 
is used, in the context of a clinical trial, as a means of staging the 
neck in patients who would otherwise undergo no elective treatment 
to the neck (either in the form of elective radiotherapy or an elective 
neck dissection).
We have applied the technique of sentinel node biopsy to patients 
instead of a “wait and see” policy to the neck. Once our initial results 
were available and accepted for publication, we were able to obtain 
ethical approval to perform such a trial in order to validate the 
accuracy of the technique in a group of patients who were to undergo 
no other treatment to the neck. Since the presence of lymph node 
métastasés rises with increased efforts to search for nodal 
disease^®®, when performing a neck dissection there is probably little 
need to search exhaustively for lymph node métastasés in a sentinel 
node. In such a case, if the sentinel node contains tumour, but is not 
seen by conventional pathological techniques, the presence of 
tumour is probably clinically insignificant. However, if sentinel node 
biopsy is to be used as a technique to upstage the neck, then the 
presence of small tumour deposits may be more significant. In order 
to search more exhaustively for small tumour deposits, the sentinel 
node was examined in more detail during our interventional study. 
Sentinel nodes were bisected, and both halves were processed for 
H&E staining. If the thickness of the two halves were greater than 
2mm, further sections were obtained for examination. In our planned 
future studies, immunocytochemistry will be used on sentinel nodes
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to further increase the detection rate of nodal métastasés®®®, as is the 
case with melanoma and breast cancer sentinel node biopsy.
Frozen section was used in our series in only one patient. In this 
case, the patient underwent sentinel node biopsy only, and no neck 
dissection. Additionally, the patient underwent free tissue transfer for 
reconstruction of the defect following tumour ablation. The sentinel 
node did not contain tumour either at frozen section or at subsequent 
formalin staining. The use of frozen section for sentinel node 
examination is a controversial topic. Arguments against the 
technique are that tissue is lost during preparation and only a small 
proportion of the node is examined. Additionally, special staining 
techniques are not performed on frozen section specimens, and it 
may be that subsequent studies in head and neck cancer show that 
the sentinel node is only an accurate means of staging the neck 
when special stains, such as immunohistochemistry and polymerise 
chain reactions to epithelial DNA are used. Accordingly, in our 
studies, we chose not to investigate frozen section other than in one 
case.
The type of case likely to benefit from a sentinel node biopsy instead 
of a wait and see policy is probably limited. Patients with small oral 
cancers with a low likelihood of metastasis are likely to benefit -  this 
group of patients would include T1/2, NO oral cancers. Additionally, 
patients with oral cancers close to or crossing the midline in which a 
bilateral neck dissection would be planned could undergo sentinel 
node biopsy on the contralateral neck side. Lastly, patients unlikely to 
benefit from a sentinel node biopsy include those patients in which 
neck access was required at the time of primary surgery, either for 
access to the tumour (eg for retromolar trigone tumours) or for 
access to vessels for microvascular reconstruction (eg lateral 
tongue/floor of mouth T2 tumours where tongue mobility would be
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compromised without a free flap reconstruction), since subsequent 
surgery to the neck in case of a pathologically positive sentinel node 
may compromise the viability of the free tissue transfer. We 
performed sentinel node biopsy without a neck dissection in one 
patient, and vessels were identified in the neck with relative ease 
without performing a neck dissection. However, if the sentinel nodes 
had contained tumour, the subsequent neck dissection would have 
been technically challenging.
The morbidity of the sentinel node procedure was not measured. In 
the initial studies, the sentinel node was harvested during the course 
of a neck dissection and it would be difficult to know whether any 
adverse effects of surgery were due to the sentinel node procedure 
or the neck dissection, reconstruction and tumour ablation surgery. In 
the group of patients where a neck dissection was only performed if 
the sentinel node was positive, the aims of the study were to 
determine whether the procedure was technically possible. Future 
studies should be directed at identifying both the morbidity and the 
cost of the procedure. In particular, shoulder function should be 
determined by using the University of Washington quality of life 
scoring system in patients undergoing sentinel node biopsy only. 
Once these studies are completed, we will have a better indication of 
the cost and morbidity associated with the procedure.
During the course of this study, other researchers have also 
performed sentinel node biopsy procedures on patients and have 
published their r e s u l t s ® ^ M o s t  centres investigating the 
procedure have performed the technique on low numbers of cases 
and to our knowledge, our series is the largest to date in oral cancer. 
Prior to this study, sentinel node biopsy had been investigated by a 
few centres with mixed success and in limited cases^ "^ ’^ "^^®’®®®’®®®.
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In an attempt to standardise the procedure and to prevent the 
situation in breast cancer where sentinel node biopsy is performed by 
different techniques according to local preferences, we have 
commenced a multicentre study in which the methodology is 
relatively fixed. From the results of this study, it will be possible to 
determine, in a homogenous group of patients who undergo a similar 
procedure, the true sensitivity of the procedure.
The protocol of our study reproduced in Chapter 12, is on the 
Canniesburn Flospital web site and forms the basis for an M.D. thesis 
for another researcher.
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CHAPTER 12: FUTURE STUDIES OF SENTINEL NODE 
BIOPSY IN HEAD AND NECK CANCER
INTRODUCTION
in this study, we have determined a method by which sentinel node 
biopsy can be performed in patients with head and neck cancer. 
Having determined the method of choice for us, we have applied the 
technique as an interventional procedure in patients to determine the 
status of the neck nodes to confirm that the procedure may be 
performed successfully out-with the context of a neck dissection. 
During this latter study, patients have undergone a therapeutic neck 
dissection and a course of post operative radiotherapy only if the 
sentinel node contained overt tumour. Following this pilot study, 
confirming the ability to harvest sentinel nodes out-with a neck 
dissection procedure, sentinel node biopsy should now be 
investigated as a means to stage the positivity or negativity of the 
regional lymph nodes. To achieve this aim, a study protocol has been 
written.
STUDY PROTOCOL
In the protocol, the primary aim is to determine whether sentinel node 
biopsy can accurately determine the presence or absence of lymph 
node métastasés in patients with T1/T2N0 oral and oropharyngeal 
cancer. Secondary aims are: to map the anatomical site of the 
sentinel node in head and neck carcinoma for various sites of 
primary lesion in the oral cavity and oropharynx, and to determine the 
role of immunohistocytochemistry and multiple step sectioning in 
identifying micrometastases in the sentinel node in the absence of 
visible métastasés by conventional staining methods.
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Patients will be invited to participate in the study if a clinical decision 
is made in the head and neck clinic for a wait and see policy to the 
neck is adopted in their management plan for clinical reasons. If the 
patient is not fit enough for a subsequent neck dissection and 
adjuvant radiotherapy, they will be ineligible for entry into the trial. 
Lastly, if the tumour is small in size but invades deeply to the extent 
that a neck dissection is warranted, then an elective neck dissection 
will be performed as is our current policy.
Patients will undergo lymphoscintigraphy up to one day prior to 
surgery, as described in the Discussion section of Chapter 3. A 
maximum of 40MBq 99mTc~labelled Human Serum Albumin (Albures 
or Nanocoll) will be injected throughout the normal mucosa 
surrounding the tumour edge and submucosa on the deep aspect of 
the tumour in a volume of approximately 0.5-1.0ml. A syringe with a 
permanently secured needle will be used for injection, to prevent 
inadvertent spillage of colloid into the mouth. Colloid will be injected 
at as many points as necessary in an attempt to completely surround 
the tumour. A mouthwash will be used immediately following injection 
to prevent pooling or swallowing of residual radioactivity by the 
patient.
Static lymphoscintigraphy will be performed at 15 minutes, 30 
minutes and one hour post injection in two planes or until the 
appearance of radioactive nodes. It is usual to see hot spots 15 
minutes post injection. If nodes are still absent one hour after 
injection, the lymph nodes are either too close to the injection site or 
radiocolloid has leaked out of the injection site.
Either a 57Co marker will be employed to trace the patient outline or 
a flood source of a 57Co or 99mTc will be placed behind the patient 
to produce a silhouette of the patient outline. From the point of view 
of radiation dose the marker pen is preferable. A gamma camera
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fitted with a low energy, genera! purpose (LEGP) collimator will be 
used to image the patient. A 20% window centred on the 140keV 
photopeak will be selected and the camera interfaced to a suitable 
computing system. The locations of radioactive lymph nodes will be 
marked on the patients’ skin: the position of a 57Co solid source pen 
will be observed on the cameras’ persistence display and the pen 
moved until its position overlies that of a radioactive node. This 
position will be then marked on the skin using indelible ink. During 
the skin marking, a lead plate of an appropriate thickness (e.g. 3mm) 
will be used to shield the injection site.
Following image acquisition a software mask will be applied to all 
images to eliminate radioactivity from the injection site. A region of 
interest, drawn around the image of the site of injection, will be used 
as the basis for the mask applied.
Two colloids are commonly used for lymphoscintigraphy in Europe: 
Albures and Nanocoll. Albures has a mean particle size of 500nm 
and is a slower moving particle that remains in first echelon (sentinel) 
nodes but requires a high density of terminal lymphatic vessels at the 
injection site. For these reason, Albures will be the colloid of choice 
in the tongue and floor of mouth. Nanocoll has a mean particle size 
of 80nm and is a faster moving colloid which finds lymphatic vessels 
despite injection into tissues with low densities of terminal 
lymphatics. However, it moves readily from sentinel nodes to 
subsequent echelon nodes and for these reasons Nanocoll will be 
the colloid of choice in non-floor of mouth/non-tongue primaries. The 
choice of colloid should be recorded.
At operation, 1-2 ml of Patent Blue V dye will be injected throughout 
the normal mucosa and submucosa surrounding the tumour. Patent 
Blue V dye will be injected prior to the skin incision to minimise the 
risk of disrupting lymphatic channels draining the primary tumour. In
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order to approximate the same injection sites as for radiocolloid, all 
injections should be made by one person. A suitable incision is made 
in the neck in such a position as to facilitate excision of the incision 
scar should a subsequent neck dissection be necessary. The hand 
held gamma probe will be used to identify radioactive sentinel nodes, 
including those marked pre-operatively during lymphoscintigraphy. 
To reduce detection of radiation from the injection site, a series of 
malleable sterilised lead plates may be used to mask the injection 
site, thus aiding in-vivo identification of radioactive nodes. 
Radioactive nodes will be excised and radioactivity within the node is 
confirmed ex-wVo. Blue stained lymphatics, if seen, will be followed 
to the first draining lymph node, which will be harvested. Sentinel 
nodes will be labelled according to their colour and radioactivity. The 
anatomical neck level of sentinel nodes will be noted. Although 
sentinel nodes should be harvested prior to treatment of the primary, 
the proximity of the sentinel node to the injection site may require a 
further search for sentinel nodes following excision of the primary. If 
sentinel nodes are sought after excision of the injection site, the 
nodes are unlikely to be blue stained.
Because of the relatively high radioactivity still present in the injection 
sites and the proximity to the sentinel node, detection of scattered 
radiation must be avoided as far as possible. As well as the use of 
lead plates as above, the gamma probe must have a well collimated 
detector which excludes gamma radiation except over a small angle 
in front of it. The pulse height analysis window should be set just to 
include the 99mTc photopeak with a cut-off on the low energy side 
at about 130 keV. The calibration should be checked at regular 
interval of not more than one month (depending on make and model 
of instrument) and a quick check of calibration should be devised to 
be carried out before each use. It may be necessary to call on
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appropriate scientific/technical assistance to ensure that the gamma 
probe is at its optimum settings and to make an estimate of its 
sensitivity at these settings.
Sentinel nodes will be fixed in 10% neutral buffered formalin and 
after fixation will be bisected through the hiium, if this is identifiable, 
or through the long axis of the node. If the thickness of the halves is 
more than 2mm the slices will be further trimmed to provide 
additional 2mm thick blocks. If sentinel nodes are found to be free 
from tumour on initial histological examination step-serial sections 
will be prepared at an additional six levels in the block at 
approximately 150 micron intervals. One H&E stained section will be 
prepared at each level. If the nodes still appear histologically 
negative, an immediately adjacent section from each level will be 
examined by immunocytochemistry using the multi-cytokeratin 
antibody AE1/AE3. (It is advisable to mount two or more short 
sequences of serial sections at each level to allow for possible 
technical problems with section preparation).
If a neck dissection is subsequently performed during the period of 
the study, all non-sentinel nodes over approximately 2.5mm in 
maximum diameter will be identified in their anatomical groups. Each 
node will be bisected through the hilum (or long axis, if the hilum is 
not identifiable) and both halves will be processed for histological 
examination. Larger nodes will be trimmed in the manner detailed 
above for sentinel nodes. One H&E stained section will be prepared 
from each block and will be examined for the presence of nodal 
involvement by tumour. The accuracy of the primary resection and 
pathological staging and grading will be performed according to 
Royal College of Pathologists guidelines.
The interpretation of the histopathology and immunocytochemistry of 
sentinel lymph nodes will be categorised as follows:-
168
P a t h o l o g y  c o d e D e s c r i p t io n
1 Tumour positive on first H&E examination
2 Initially tumour negative, but tumour positive on examination 
of H&E of step serial sections
3 Negative at stages 1 and 2 but positive by 
immunohistochemistry. To be categorised as tumour positive 
there must be cells which are both positive by 
immunocytochemistry and are cytologically seen to be 
nucleated cells with the characteristics of viable epithelial 
cells in both the immunocytochemical preparation and the 
serial H&E section. Cytokeratin positivity lacking the 
cytological features of viable tumour cells is categorised as 4.
4 Cytokeratin positivity not showing the features of viable 
tumour cells. This positivity is likely to represent either dying 
tumour cells, possibly apoptotic cells, characterised by being 
eosinophilic bodies lacking normal nuclei, or macrophages 
with phagocytosed tumour products. Usually these cells will 
be single and not small cohesive groups. The decision to 
allocate nodes to this category requires careful comparison of 
the serial H&E and immunocytochemical preparations.
5 Negative at all stages.
FURTHER TREATMENT FOR PATIENTS WITH SENTINEL LYMPH 
NODES CONTAINING TUMOUR
In the event that any lymph node contains viable tumour either by 
routine histology or through immunohistochemistry and multiple
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sectioning, the patient will undergo a radical or modified radical neck 
dissection. For tumours that drain to lymph nodes on both sides of 
the neck, a neck dissection will only be performed on the side of the 
neck in which a sentinel node containing tumour was found. The 
neck dissection should take place within four weeks of the sentinel 
node biopsy, and any adjuvant radiotherapy should start within six 
weeks of the neck dissection. Radiotherapy should not be 
administered prior to neck dissections.
Patients will undergo further treatment to the neck following sentinel 
node biopsy according to the following flow chart:
Sentinel node examined
Pathology code 1, 2 or 3 Pathology code 4 or 5
Radical or modified 
radical neck dissection
No further treatment to the neck 
No prophylactic neck radiotherapy 
or further surgery
Neck staged pathologically pNO neck
Further treatment 
as per unit protocol 
Entry into other trials permitted
Entry into other trials to electively 
treat regional disease 
not permitted
FOLLOW-UP
Follow-up will take place for all patients entered into the trial. Patients 
will be seen three monthly for the first year, four monthly for the 
following two years and six monthly until 5 years post sentinel node 
biopsy.
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At any stage, if nodal disease is detected, patients will be offered 
treatment to the neck in the form of surgery. All other treatments for 
metastatic disease will be given according to local protocols, 
however, patients with regional failure must undergo a neck 
dissection, if fit for surgery.
Should the technique prove to be valuable in determining the 
pathological status of the lymph nodes in the neck, it may be used as 
an alternative to elective lymph node dissections.
CONCLUSIONS
Sentinel node biopsy is an exciting new development in head and 
neck cancer. Our initial results indicate that the technique may be 
able to identify early nodal métastasés in clinically NO necks. This 
should be investigated further in formal clinical trials. Since the 
number of cases which any individual centre is able to perform is low, 
trials for head and neck cancer sentinel node biopsy should be 
conducted using strict protocols and should be multicentre trials.
Single unit trials will inevitably have low patient numbers recruited. 
Accordingly, it is difficult to organise a randomised controlled trial to 
initially investigate sentinel node biopsy as an alternative to a wait 
and see policy and subsequently as an alternative to neck 
dissections. Nevertheless, to fully investigate the technique, large 
scale multicentre trials should be organised with control groups, and 
with survival and recurrence end points.
By researching the technique in this manner, meaningful results from 
studies with reasonable statistical power will emerge with time.
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APPENDIX 1: ETHICAL CONSIDERATIONS
Ethical approval was obtained from the local ethics committee at the 
Royal Infirmary, 84 Castle Street, Glasgow, prior to starting this study 
(approval reference numbers: BU98006 and BU99001). An
Administration of Radioactive Substances Approval Committee 
(ARSAC) certificate was obtained to inject radiocolloid into patients 
entered into the study. Dr H.W Gray was the lead consultant in 
charge of administering the radiopharmaceuticals, and, within the 
remit of the certificate, permission was given to Mr T Shoaib to 
administer radiocolloid.
All patients entered into this study were given full informed consent 
prior to sentinel node biopsies being performed. There were two 
groups of patients on whom sentinel node biopsies were performed, 
and each was counselled differently. The first group underwent 
sentinel node biopsy in addition to a neck dissection, whereas the 
second group underwent a neck dissection only if the sentinel node 
was subsequently found to contain tumour. The patient information 
and consent forms for these two groups are reproduced.
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PATIENT INFORMATION AND CONSENT FORM FOR PATIENTS 
UNDERGOING SENTINEL NODE BIOPSY AND NECK 
DISSECTION
T it l e  o f  P r o j e c t : L y m p h  N o d e  M a p p in g  A n d  Id e n t if ic a t io n  O f
S e n t in e l  L y m p h  N o d e  In  H e a d  A n d  N e c k  C a n c e r
You have been diagnosed as suffering from either a squamous cell 
carcinoma or malignant melanoma of the skin in your head and neck 
region or squamous cell carcinoma in your oral cavity. You are 
shortly to be admitted to undergo surgery for this cancer and as part 
of this you will be undergoing a neck dissection (removal of a group 
of lymph nodes from one side of your neck).
It is well recognised that head and neck cancers, both of the skin and 
of the oral cavity, can spread to lymph nodes although at the present 
time the exact mechanism by which this occurs is unknown. We 
would like to try and establish the mechanism by which tumours 
spread in this manner so that it may be possible in the future to 
improve the treatment of cancers such as the one you have. Prior to 
surgery, we would like to inject a small quantity (0.5ml) of blue dye 
and a small dose of a radioactive drug (40MBq in 0.5ml-1.0ml) 
around your tumour. The radioactive drug will be injected at the 
Nuclear Medicine Department at the Royal Infirmary and will be 
followed by a scan of your head and neck. As a result injecting blue 
dye into your tumour, your skin colour and urine may be tinged blue 
for a day or so after your surgery. This possible colour change will 
have settled by the time you are ready for discharge home. Also, it 
will be necessary for you to avoid close contact with pregnant women 
for 24 hours following the injection of the radioactive drug. The
173
remainder of your routine assessments and your treatment will be 
then undertaken according to our normal schedule.
If you agree to take part in this research project it may be of little or 
no benefit to you but the results may help other patients in the future. 
Should you not wish to take part in the project or at any time should 
you wish to stop taking part, you may do so. The care which you 
receive and your proposed treatment protocol will not be affected in 
any way. If you agree to take part in this research project, your own 
general practitioner will be told and will be given detailed information 
about the care you will receive. Should you require more detailed 
information concerning this project, please do not hesitate to ask and 
we will provide a more detailed description of the project.
If you are pregnant or likely to become pregnant, you should not take 
part in this research study.
Consent
I, (Name)........................................................................   of
(Address)..................... ...........................................................................
agree to take part in the Research Project/Study Programme 
described above.
Dr/Mr.......................         has
explained to me what I have to do, how it might affect me and the 
purpose of the Research Project/Study Programme.
Signed................ ...................................................................................
Date.................... ................... ...............................................................
Witness............... .................................................................................
Date............................................................... ..........................................
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PATIENT INFORMATION AND CONSENT FORM FOR PATIENTS 
UNDERGOING SENTINEL NODE BIOPSY ONLY
CONSENT FORM
TITLE OF PROJECT: Sentinel node biopsy to upstage clinically false 
negative necks in patients with oral cancer
You have been diagnosed as suffering from a squamous cell 
carcinoma of your oral cavity and are shortly to undergo surgery for 
this cancer.
It is well recognised that head and neck cancers of the oral cavity, 
can spread to lymph nodes although at the present time the exact 
mechanism by which this occurs is unknown. We would like to try 
and establish the mechanism by which tumours spread in this 
manner so that it may be possible in the future to improve the 
treatment of cancers such as the one you have. Prior to surgery, we 
would like to inject a small quantity (0.5ml) of blue dye and a small 
dose of a radioactive marker (40MBq in 0.5ml-1.0ml) around your 
tumour. The radioactive marker will be injected at the Nuclear 
Medicine Department at the Royal Infirmary and will be followed by a 
scan of your head and neck. As a result of injecting blue dye into 
your tumour, your mouth colour and urine will be stained blue for a 
day or so after your surgery. This colour change will have settled by 
the time you are ready for discharge home. The remainder of your 
routine assessments and your treatment will be then undertaken 
according to our normal schedule.
If you agree to take part in this research project it may be of little or 
no benefit to you but the results may help other patients in the future. 
Should you not wish to take part in the project or at any time should 
you wish to stop taking part, you may do so. The care which you 
receive and your proposed treatment protocol will not be affected in
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any way. If you agree to take part in this research project, your own 
general practitioner will be told and will be given detailed information 
about the care you will receive. Should you require more detailed 
information concerning this project, please do not hesitate to ask and 
we will provide a more detailed description of the project.
If you are pregnant or likely to become pregnant, you should not take 
part in this research study.
CONSENT
I, (Name)..............................................     of
(Address)..................... .............................................................. ............
agree to take part in the Research Project/Study Programme 
described above.
Dr/Mr.......................................................... ......................... has
explained to me what I have to do, how it might affect me and the 
purpose of the Research Project/Study Programme.
Signed....................................................................................................
Date..................................................................................
Witness....................... ............................................................................
Date.................................................................................
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PATIENT INFORMATION FORM
TITLE OF PROJECT:
Sentinel node biopsy to upstage clinically false negative necks in 
patients with oral cancer
INTRODUCTION
Oral cancer spreads by the lymphatic channels to lymph nodes 
located in the neck. In patients with oral cancer, we always examine 
the neck for signs of spread, and if spread has occurred we perform 
an operation called a neck dissection. A neck dissection is an 
operation to remove a large proportion of the lymph nodes in the 
neck and is considered major surgery. Since major surgery carries 
some risks, we are reluctant to perform neck dissections on patients 
whom we think will not benefit from it. At the moment, however, the 
only way of determining whether spread to the neck has occurred or 
not is to perform a neck dissection and sometimes we perform a 
neck dissection for the sole reason to find out if spread has occurred 
or not.
in your case, we will not be performing a neck dissection at the 
moment, because we feel that spread to the lymph nodes has not 
occurred. Our normal practice for patients, such as you, is to observe 
and examine you every few months. By doing this, if spread has 
occurred we will be able to detect this early, and give you the 
treatment you need quickly.
We are always looking for ways to improve the treatment and 
investigations we offer people. Currently, we are performing a new 
technique to determine whether we can make improvements to the 
care of patients with oral cancer. We would like to invite you to enter 
a clinical trial of a procedure called “Sentinel node biopsy”. This
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leaflet will explain the procedure, tell you how it is performed and will 
answer some of the questions you may have.
SENTINEL NODE BIOPSY
Sentinel node biopsy is a procedure that has been performed for 
patients since the early 1990’s. In patients with malignant melanoma 
(a type of skin cancer) and breast cancer, sentinel node biopsy has 
been shown to be a very good way of telling whether spread of the 
cancer has occurred or not. We would like to see if sentinel node 
biopsy can tell us whether spread has occurred in patients with oral 
cancer.
Sentinel node biopsy is a technique that involves two injections. One 
of these Injections will be given while you are awake and one while 
you are under anaesthesia. The first injection is given into the mouth 
and the substance injected is a radioactive protein. The injection will 
be given in the Nuclear Medicine Department at the Royal Infirmary. 
The dose of radioactivity used is very low in comparison to the doses 
we use for other investigations in Nuclear Medicine. After the 
injection, a scan will be performed of your neck to image the injection 
as it travels from your mouth to the glands in the neck. The scan 
takes about half an hour to one hour in total.
The second injection is given while you are asleep under 
anaesthesia. The injection given is a blue dye and colours the lymph 
channels and lymph nodes blue. When we perform a sentinel node 
biopsy, we can find blue stained lymph nodes and trace radioactivity 
with a gamma-probe to find the sentinel node. The sentinel nodes 
are sent to the pathology laboratory where the Pathologist examines 
the node for the presence of tumour cells. If any tumour is seen in 
the sentinel node, we will offer you further treatment to the lymph 
nodes in the neck.
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CHANGES TO YOUR TREATMENT
By agreeing to enter our trial, you are agreeing to have a sentinel 
node biopsy performed. The rest of your treatment and investigations 
will be performed according to our usual schedule. Sentinel node 
biopsy Is an investigation which will be performed in addition to your 
usual treatment. Since it is an un proven theory in oral cancer, we 
cannot guarantee that it will be successful in identifying cancer 
spread, if spread has already occurred.
SIDE EFFECTS
Sentinel node biopsy has been performed for several years, and 
there are very few side effects associated with it. These are:
Blue staining of the urine. Since we inject blue dye into the tissues 
around your tumour, and since the dye is removed by your kidneys, 
for about one day after your operation, your urine will be stained 
blue.
Hypersensitivity. There have been a few reports of people being 
allergic to the blue dye we inject. This is more common in people 
who suffer allergies to other things. If you tend to suffer from 
allergies, please let us know.
BENEFITS TO YOU
If you agree to take part In this research project it may be of little or 
no benefit to you but the results may help other patients in the future. 
Should you not wish to take part in the project or at any time should 
you wish to stop taking part, you may do so. The care which you 
receive and your proposed treatment protocol will not be affected in 
any way. If you agree to take part in this research project, your own 
general practitioner will be told and will be given detailed information 
about the care you will receive. Should you require more detailed
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information concerning this project, please do not hesitate to ask and 
we will provide a more detailed description of the project.
FURTHER INFORMATION
If you or your family have any questions are require any further 
information, please contact;
Mr T. Shoaib (Head and Neck Research Fellow) or Mr D.S. Soutar 
(Consultant Plastic Surgeon) at Canniesburn Hospital.
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APPENDIX 2: PUBLICATIONS AND PRESENTATIONS
The following publications and presentations have been produced as 
a result of the work within this thesis.
PUBLICATIONS
A suggested method for sentinel node biopsy in squamous cell 
carcinoma of the head and neck. Shoaib T. Soutar DS. Prosser JE. 
Dunaway DJ. Gray HW. McCurrach GM. Bessent RG. Robertson 
AG. Oliver R. MacDonald DG. Head & Neck. 21(8);728~733, 1999 
Dec. Head & Neck, 22(7): 733-735, 2000 Oct (Author's reply to 
comments)
Sentinel node biopsy in head and neck cancer. Shoaib T. Soutar DS. 
Current opinion in otolaryngology and head and neck surgery. 
9(2):79-84, 2001 Apr.
The accuracy of head and neck cancer sentinel node biopsy in the 
clinically NO neck. Shoaib T, Soutar DS, MacDonald DG, Camilleri 
IG, Dunaway DJ, Gray HW, McCurrach GW, Bessent RG, McLeod 
TIP, Robertson AG. Cancer, 91(11):2077-2083, 2001 June
Cost effectiveness of SNB as an alternative to elective neck 
dissections in patients clinically NO head and neck squamous cell 
carcinoma. Ross GL, Soutar DS, Shoaib T, Camilleri I, Gray HW, 
Bessent RG, MacDonald DG. Oral Oncology 2001(7):400-404
Sentinel node biopsy to target lymph node dissection at the clinically 
false negative neck in head and neck. G Ross , D Soutar, T Shoaib, 
HW Gray, IG Camilleri, RG Bessent, DG MacDonald, cancer. Oral 
Oncology 2001(7):393-396
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The history of sentinel node biopsy in Canniesburn. G Ross, D 
Soutar, T Shoaib, HW Gray, IG Camilleri, RG Bessent, DG 
MacDonald. Oral Oncology 2001 :(7)405-408
The first international conference on sentinel node biopsy in mucosal 
head and neck cancer and adoption of a multicenter trial protocol. 
Ross GL, Shoaib T, Soutar DS, MacDonald DG, Camilleri IG, 
Bessent RG, Gray HW. Ann Surg Oncol 2002 May;9(4):406-10
Sentinel node biopsy: the technique and the feasibility in head and 
neck cancer. C. Von Buchwald, A. Bilde, T. Shoaib, and G. Ross, o r l
J.Otorhinolaryngol.Relat Spec. 64 (4):268~274, 2002.
The use of sentinel node biopsy to upstage the clinically NO neck in 
head and neck cancer. Ross G, Shoaib T, Soutar DS, Camilleri IG, 
Gray HW, Bessent RG, Robertson AG, MacDonald DG. Arch 
Otolaryngol Head Neck Surg. 2002 Nov; 128(11): 1287-91.
PEER REVIEWS
In autumn 2001 I performed peer review for the British Journal of 
Cancer on the following manuscript: Sentinel node biopsy in NO 
cancer of the larynx and pharynx. JA Werner, A-A Dunne, A 
Ramaswamy, BJ Folz, BM Lippert, R Moll, Th Behr
PERSONAL PRESENTATIONS TO LEARNED SOCIETIES 
I n t e r n a t io n a l  C o n f e r e n c e s
Initial Results of Sentinel Node Biopsy in Oral Cancer. Abstract in: 
Eur J NucI Med (1999) 26(suppl):S70. T. Shoaib*, D.S. Soutar, J.E. 
Prosser, D.J. Dunaway, H.W. Gray, G.M. McCurrach, R.G. Bessent, 
R. Oliver, D.G. MacDonald. “1st International Congress on the
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Sentinel Node in the Diagnosis and Treatment of Cancer”, 
Amsterdam, April 7th-10th, 1999. Oral presentation.
Success with sentinel node biopsy in head and neck cancer using 
blue dye and radiocolloid. T. Shoaib, D.S. Soutar, D.J. Dunaway, I.G. 
Camilleri, H.W. Gray, D.G. MacDonald. European Association of 
Plastic Surgeons. Berlin. June 2, 2000. Oral Presentation
The accuracy of sentinel node biopsy in the clinically NO neck. T. 
Shoaib*, D.S. Soutar, D.J. Dunaway, I.G. Camilleri, H.W. Gray, G.M. 
McCurrach, R.G. Bessent, T.I.F. MacLeod, D.G. MacDonald. The 5th 
International Conference on Head and Neck Cancer. San Francisco, 
July, 2000. Oral Presentation
Sentinel node biopsy in patients undergoing neck dissection (invited 
presentation). International Symposium on Métastasés in Head and 
Neck Cancer: Advances in Experimental and Clinical Oncology, 
Marburg, Germany. January 25th-27th, 2001
The History of sentinel node biopsy (invited presentation). The 1st 
International Conference on Sentinel Node Biopsy in Mucosal Head 
and Neck Cancer, Glasgow. June 25, 2001.
Sentinel node biopsy in patients undergoing neck dissection (invited 
presentation). The 1st International Conference on Sentinel Node 
Biopsy in Mucosal Head and Neck Cancer, Glasgow. June 25, 2001.
Sentinel node biopsy in patients undergoing neck dissection. 
Canniesburn Reunion Conference, Glasgow. July 1, 2001.
N a t i o n a l
Initial Success In Performing Sentinel Node Biopsy In Patients With 
Head and Neck Cancer. T. Shoaib, D.S. Soutar, J.E. Prosser, D.J. 
Dunaway, A.G. Robertson., H.W. Gray, G.M. McCurrach, R.G. 
Bessent, D.G. MacDonald. British Association of Head and Neck
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Oncologists, Annual General Meeting, Royal College of Physicians, 
London, April 30th 1999. Oral presentation.
Sentinel Node Biopsy in Oral Cancer: Initial Results. J. Prosser, T. 
Shoaib, D.S. Soutar, G.M. McCurrach, D.J. Dunaway, H.W. Gray. 
British Nuclear Medicine Society. Brighton, May 11th, 1999. Oral 
presentation.
Techniques to assist sentinel node biopsy in head and neck cancers. 
Abstract in: NucI Med Commun (2000);21(4):387. T. Shoaib, D.S. 
Soutar, I.G. Camilleri, D.J. Dunaway, G.M. McCurrach, R.G. 
Bessent, H.W. Gray. British Nuclear Medicine Society. Brighton April 
12th, 2000. Oral Presentation. PRIZE WINNING PRESENTATION: 
3RD BEST ORAL PRESENTATION
Future studies of sentinel node biopsy in head and neck cancer. T. 
Shoaib, D.S. Soutar, I.G. Camilleri, H.W. Gray, A.G. Robertson, D.G. 
MacDonald. British Association of Head and Neck Oncologists 
Annual General Meeting, London. April 28, 2000. Oral Presentation
Sentinel node biopsy in head and neck cancer. T. Shoaib, D.S. 
Soutar, D.J Dunaway, I.G. Camilleri, H.W. Gray, G.M. McCurrach, 
R.G. Bessent, T.I.F. MacLeod, D.G. MacDonald. British Association 
of Plastic Surgeons (3rd European Appointed Meeting). Birmingham, 
July 6 th, 2000. Oral Presentation
The anatomical site of sentinel nodes in mucosal head and neck 
cancer. T. Shoaib, D.S. Soutar, D.G. MacDonald. British Association 
of Plastic Surgeons. July 4, 2001. Oral Presentation
R e g io n a l
Sentinel node biopsy in malignant melanoma and head and neck 
cancer. T. Shoaib, J. Prosser, D.S. Soutar, D.J. Dunaway, H.W. 
Gray, G.M. McCurrach, R.G. Bessent, D.G. MacDonald, R.M.
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MacKie. “The Scottish Scientific Meeting”, Royal College of 
Physicians of Edinburgh, March 5th, 1999. Poster presentation.
Pathological aspects of sentinel node biopsies in oral cancer. D.G. 
MacDonald, T. Shoaib, D.S. Soutar. Scottish Science Meeting. 
Stirling, September 1 2000. Poster presentation. WINNER OF BEST 
POSTER PRIZE
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